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Six iridium, rhodium and ruthenium half-sandwich organometallic complexes (C1-C6) of the ligand 2,2-
dipyridilamine with either a chlorido and iodido ancillary ligand were synthesized using a reported 
method and their biological activity was investigated. C1-C6, complexes bearing a PF6- counterion, 
have been reported in literature. Single crystal structures of iridium (C1) and rhodium (C2) chlorido 
complexes were solved and both were found to have crystallised in the orthorhombic P212121 space 
group. The aqueous solubility of C1-C6 ranged from poor (<10 µg/mL) to good solubility (> 60 µg/mL).  
The ruthenium-iodido complex C6 was the least soluble up to 7 µg/mL. Hydrolysis studies were 
conducted, and it was found that chlorido complexes C1, C5 and C6 did not undergo hydrolysis. The 
chlorido complexes C2 and C3 did undergo hydrolysis, however, complete displacement of the 
chlorido with deuterium oxide did not occur.  
Novel complexes C7-C12, analogues of C1-C6 bearing a NO3- counterion were also synthesized using 
an adapted method of the PF6- complexes. The crystal structures of complexes C7 and C9 were solved. 
Iridium chlorido complex C7 was found to crystallise in the monoclinic P21/c space group and 
ruthenium chlorido complex C9 was found to crystallise in the triclinic P-1 space group. Complexes C7, 
C8, C9, C11 and C12 were found to have good solubility to a maximum concentration of 200 µM. 
Iridium iodido complex C8 was moderately soluble >41 µg/ml. Hydrolysis studies of complexes C7-C12 
showed that chlorido complexes C8 and C9 and iodido complex C12 were hydrolysable. Generally, 
chlorido complexes for both PF6- and NO3- counterions were relatively easily hydrolysable compared 
to iodido complexes with the exception of chlorido complex C7 and iodido complex C12. 
The in vitro biological antiplasmodial activity of the ligand, 2,2-dipyridilamine, and complexes C1-C6 
was evaluated against two Plasmodium falciparum strains, complexes C7-C12 were not evaluated due 
to time constraints. The ligand was found to be inactive up to a concentration of 5mM against 3D7 
strain, a chloroquine sensitive strain of Plasmodium falciparum parasite. The complexes showed 
activity against the 3D7 strain, however, the complexes were not as active as currently used 
antimalarial drugs. Rhodium complexes C2 (IC50 = 4.72 µM) and C5 (IC50 = 5.76 µM) were the most 
active and iridium chlorido complex C1 (IC50 = 8.93 µM) was the least active amongst complexes C1-
C6. Activity of the chlorido versus iodido complexes of iridium and rhodium were presumed to be 
associated with their relative solubility in aqueous based medium, the more soluble complexes were 
more active. This argument was not applicable for the ruthenium complexes, the less soluble complex 
C12 (IC50 = 7.91 µM) showed better activity than the more soluble complex C6 (IC50 = 7.57 µM). The 
ligand and complexes showed no activity against chloroquine sensitive NF54 strain in a two- and three-
day assay.  The inactivity may be related to the use of hypoxanthine in the growth media which could 
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List of abbreviations: 
  
2,2-Dipyridylamine Dpa 
3D7 Chloroquine sensitive Plasmodium falciparum strain 
𝜇M Micromolar 
A2780 Cancer cell line 
ACT Artemisinin-based combination therapy 
CHO Chinese Hamster Ovarian cancer cells 
CQ Chloroquine 
CQR Chloroquine resistant  
CQS Chloroquine sensitive 
DCM Dichloromethane 
Dd2 Chloroquine resistant Plasmodium falciparum strain 
DHA Dihydroartemisinin 
DHFR Dihydrofolate reductase  
DHPS Dihydropteroate synthase 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
FQ Ferroquine 
IC50 Half maximal inhibitory concentration 
IPC5202 Artemisinin-resistant Plasmodium falciparum strains  
K1 Multi-resistant Plasmodium falciparum strain 
LSG Late stage gametocyte  
MLEM Model List of Essential Medicines 
MOA Mechanism of action 
NAI Naturally Acquired Immunity  
NF54 Chloroquine sensitive Plasmodium falciparum strain 
nm Nano molar 
P. berghei Plasmodium berghei 
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P. falciparum Plasmodium falciparum 
P. knowlesi  Plasmodium knowlesi 
P. malariae Plasmodium malariae 
P. ovale  Plasmodium ovale 
P. vivax  Plasmodium vivax 
p-cym Para-Cymene 
PGM Platinum group metal 
ppm Parts per million 
RBCs Red blood cells 
RI resistance indices  
SCE Saturated calomel electrode 
Sep Septet 
WHO World Health Organization 
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Organometallic complexes as antimalarials: A review 
1.1.  Introduction 
Research into the use of metal complexes in the medicinal field has been growing. Since researchers 
have found that incorporating metal ions into organic pharmacophores can improve their therapeutic 
efficacy.1,2 The successful application of cisplatin as an anticancer agent has brought attention to the 
potential application of metal complexes as therapeutics.3 This investigation into metallo-drugs is far 
advanced with some new metal containing drugs already in use and others in clinical trials.4 There are 
several properties offered by metals that can be taken advantage of in order to design better 
therapeutic agents.4 Different metals possess a wide range of coordination numbers, geometries, 
thermodynamic and kinetic properties as well as accessible redox states.4 With the study of metal 
complexes as viable new medicines gaining momentum, it is important for us to better understand 
their interactions in a biological environment and how it could affect their therapeutic efficacy. 
Several metal complexes with proven efficacy against P. falciparum, one of the causative agents of 
malaria, have been reported.1 Malaria is one of the deadliest diseases in the world, threatening more 
than one third of its population. It is caused by parasites of the Plasmodium genus which are 
transmitted into the blood stream through the bites of female Anopheles mosquitoes.5 Malaria is 
mostly prevalent in tropical regions thriving in large areas of Africa and South-East Asia, some parts of 
South and Central America, as well as the Eastern Mediterranean and Western Pacific. It thrives in 
these countries due to their tropical or subtropical climates which are favourable for mosquitoes to 
proliferate, i.e. survive and be able to reproduce6. In high risk areas, the most susceptible people are 
pregnant women and infants owing to the fact that they have compromised or no naturally acquired 
immunity (NAI) to the disease.7 A greater risk is observed for underprivileged people who have little 
to no access to health care.8  
According to the World Health Organization (WHO), in  2019, an estimated 229 million cases of malaria 
were reported worldwide, an increase of 1 million cases since 2018.9 This resulted in about 409 000 
deaths. Africa accounts for 93% of reported malaria cases and 89% of deaths.9 The P. vivax parasite is 
mostly widespread in the WHO region of America where it accounts for about 72.3% of all its reported 
malaria cases.6 There have been inconsistencies in reported cases for individual countries with some 
countries having more cases while others have a reduced number of cases over the course of the 
years. The mortality rate on the other hand displays a decrease since 2010. From the estimated total 
of 409 000 deaths reported, about 67% of these were the deaths of children under the age of 5 years. 
Although with reduction in malaria cases and reported deaths, the statistics are still significantly high 
and alarming. Nonetheless, according to the WHO there were 10 countries that successfully 
eliminated malaria during the period 2010-2019 with some countries expected to have eradicated the 
P. falciparum malaria by 2025.6 
Malaria places the biggest toll on the African continent.6 The social and economic toll on individuals, 
families, communities as well as governments can be high.10 It has been estimated that at least US$ 
12 billion per year is used for all necessary costs which include, purchase of drugs and supplies for 
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treatment; and public health interventions against malaria.10 Consequently, considerable economic 
growth is lost.8 
Access to treatment of malaria is often problematic in areas of low-income. This is worsened by the 
escalation of drug resistance with one of the first line antimalarial drugs, chloroquine (CQ), becoming 
increasingly ineffective in nearly all parts of the world where malaria caused by P. falciparum is 
found.11 Today, CQ is only used for the treatment of P. vivax infections in regions where resistance 
hasn’t been developed.11 As of 2016, Artemisinin-based combination therapies (ACTs) have been 
declared as the first and second lines (most effective) of treatment for uncomplicated cases of malaria 
as well as CQ resistant (CQR) malaria caused by the P. vivax parasite.11 The use of ACTs has significantly 
decreased the global malaria burden.12 In the past, access to ACTs has been reported to be limited 
but, an increase in procurement of ACTs treatment courses has been observed in recent years.11 
However, for some of these antimalarial drugs, reports of their resistance are beginning to rise.  
 
To overcome the spread of drug resistant parasites of malaria, new drugs incorporating metal 
derivatives of current antimalarial drugs are being investigated.13 Drugs of this nature are of great 
value as they include both an organic pharmacophore, i.e., a compound’s substructure responsible for 
a particular pharmacological interaction with its intended target, as well as a metal. This rapid 
advancement of the study of organometallic complexes as antiplasmodials could potentially find 
candidates that are more efficacious against resistant and sensitive strains than pre-existing drugs. 
This review focuses on the use of organometallic complexes in the treatment of malaria.  
 
1.2.   What is malaria: Causes of malaria, Life cycle of the parasite. 
Malaria is caused by the protozoan Plasmodium parasites. It is a febrile disease, i.e. has fever-like 
symptoms such as headache, muscle aching, dizziness, chills, diarrhoea, etc. Due to the nature of its 
symptoms, diagnosis can be difficult. If not treated in its early stages, malaria can become severe and 
may have lethal complications such as anaemia, renal failure, and convulsions.  
There are several types of Plasmodium parasite that cause malaria. Five of these species that are 
known to cause human malaria are P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi 
(zoonotic). By zoonotic, this implies that P. knowlesi normally infects animals but may be transmitted 
to humans on rare occasions.14 P. falciparum and P. vivax are the most prevalent and dangerous, with 
P. falciparum being the most severe, resulting in higher mortality rate, and P. vivax often causing 
notable morbidity.  The P. falciparum parasite is the most prevalent, especially in the WHO region of 
Africa.14  
Antimalarials are developed on the basis of the parasite’s biological profile as well as what stage of 
the parasite life cycle the antimalarial could target.2 The life cycle of plasmodium parasite comprises 
two different stages with each occurring in different hosts, the human which is the intermediate host 
(I-IV, Figure 1) where the asexual phase occurs, and the female Anopheles mosquito, the definitive 
host (V and VI, Figure 1) where the sexual phase of parasite occurs.15 In the asexual phase, asexual 
reproduction takes place. This process entails splitting and forming generations (known as 
schizogony), resulting in the formation of merozoites which then develop into male and female 
gametocytes in the intermediate host.15 In the sexual phase, sexual reproduction takes place, 
fertilisation of gametes occurs in a process known as sporogony to produce sporozoites.15 
 




Figure 1: Life cycle of plasmodium malaria parasite. Taken from Epidemiology of Infectious Diseases.2 
 
When a parasite carrying female Anopheles mosquito bites a human, it injects sporozoites (step I, 
Figure 1) into the human body. The sporozoites travel through the bloodstream to the liver (step II, 
Figure 1) and starts infecting the hepatocytes (Figure 1).16 Once it has infected the liver cells, it pushes 
its nucleus to the periphery. The nucleus of the sporozoites multiply and eventually develop into 
schizonts which contain merozoites.15 
When mature, the schizont bursts and merozoites are released into the bloodstream. Once in the 
bloodstream, they start to invade red blood cells (RBCs) (step III, Figure 1).16 Once inside the RBC, 
merozoites situate themselves in the intraerythrocytic parasitophorous vacuole. There it develops into 
a ring-like structure appearing as a round body within a vacuole in its centre which is referred to as a 
young trophozoite.15 
The trophozoite feeds on the haemoglobin proteins of the erythrocyte leaving behind a hematin globin 
pigment side product called malarial pigment or hemozoin pigment17, as biocrystals18, so as to prevent 
free heme since it is toxic to the parasite.17 This pigment is different for every malaria species and it 
can therefore be used as an identification tool to determine which type of plasmodium parasite 
caused an infection. As the ring form or trophozoite develops, it enlarges in size and becomes irregular 
in shape and is termed the amoeboid form or late trophozoite form. As the amoeboid form develops 
further, its nucleus starts dividing by mitosis, then the cytoplasm also starts to divide into 
“mechoschizonts”. The mechoschizonts eventually bursts releasing merozoites, hemozoin and 
pyrogens into the bloodstream. Once pyrogens are released, the host begins to experience fever-like 
symptoms. This incubation period takes about 7-18 days. How long the infection takes before showing 
symptoms after infection depends on which parasite caused infection.15 
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The merozoites then begin to invade “healthy” or uninfected erythrocytes. This provide evidence as 
to why malaria causes anaemia since RBCs are being damaged. Once the erythrocyte cycle has 
occurred a number of times, the merozoite no longer forms the trophozoite or schizont, instead they 
form male and female gametocytes (step IV, Figure 1).19 These gametocytes are then taken up by a 
mosquito when it feeds on the blood of this infected human16.  
A female Anopheles mosquito feeds on the blood of a host containing RBCs with male and female 
gametocytes (step V, Figure 1). The mosquito then digests the gametocytes which are then released 
into the gut of the mosquito. The female gametocytes undergo a process called maturation to form 
female gametes/ macrogametes. Male gametocytes on the other hand divide to form male gametes/ 
microgametes. Nuclear material and cytoplasm of male gametocyte divides to form 8 microgametes 
with long actively motile whip-like filaments. Male and female gametes undergo fertilization to form 
a zygote. The zygote develops into the ookinete, which further develops into the oocyst, i.e., a 
multiplicatory phase within which numerous sporozoites are seen. Sporozoites begin to develop in 
here and then multiply causing rupture. Sporozoites are then released and reach the salivary glands 
of the mosquito. Once in the salivary gland, the mosquito can then bite another human and the cycle 
repeats itself (step VI, Figure 1).15 
Different antimalarials target different stages of the life cycle of the malaria parasite in the 
intermediate host, i.e., human. Various sites at which the parasite life cycle occurs allow for different 
mechanisms of action (MOA) to be possible. The most productive method is by inhibiting the 
formation of hematin.20 
 
1.3.   History of organic antimalarials 
 
Traditional herbal remedies were initially used for the treatment of malaria for many centuries.12 The 
isolation and development of chemicals effective in the treatment of malaria began in the 1800’s. 
Despite some of these therapeutics being very effective, there were limitations. These include side 
effects as well as malaria strains becoming resistant to the antimalarial drugs as time progressed.21 
Listed below are some examples of the earliest antimalarial drugs to be isolated and developed. 
The first successful treatment of malaria was by quinine (Figure 2), a chemical found in the bark of  the 
cinchona tree in 1820.12 To this day, quinine is known to be one of the greatest drugs for treatment of 
this disease.21 Since 2006, quinine is no longer regarded as a front-line defence drug for treatment 
seeing that the Plasmodium parasite has developed resistance against the drug, with the first report 
of resistance in the 1980’s.21 However, it is still used in cases where artemisinins are unavailable.21  




Figure 2: Structures of antimalarials that have been used in the past. 
 
Mepacrine (Figure 2) is another antimalarial drug that was developed in the 1920’s22 that was mainly 
used as a prophylactic as well as for the cure thereof.21 However, the use of this drug has declined due 
to its undesirable side effects21 linked to the liver such as acute liver injury which can lead to death.22 
CQ (Figure 2) was used in the treatment of all types of malaria with very little side effects.21 Its MOA 
involves inhibiting hemozoin biocrystallization (prevention of crystallisation of heme produced by 
malaria parasite in RBCs), a well-known method of detoxifying in mammals.12 Although a good 
antimalarial drug, several malaria strains began to show resistance to CQ. The first report of resistance 
was in the 1950’s, and now CQ is mainly used to treat non-resistant strains caused by P. vivax. 21 
Mefloquine (Figure 2), a drug which was used both as a prophylactic and treatment,21 was developed 
with the aim of treating CQR strains of malaria. It was later, reported to have resistant strains.21 Due 
to its undesirable side effects linked to central nervous system toxicity, mefloquine is not used 
extensively anymore.21 Halofantrine (Figure 2), initially intended for treatment of all kinds of malaria 
including multidrug resistant strains of P. falciparum, has a similar mode of action to quinine as well 
as mefloquine. Its use declined after it was reported to have been associated with the death of a 
patient due to cardiotoxicity.23 The use of piperaquine,  (Figure 2) a synthetic drug believed to be as 
efficacious as chloroquine and more tolerable in the treatment of P. falciparum and P. vivax malaria 
plunged as a result of growing drug resistance of P. falciparum malaria strains.24 Similar to chloroquine, 
piperaquine treats malaria by inhibiting the formation of hemozoin. However, piperaquine gained 
back its reputability when it was established that combining it with an artemisinin derivative produces 
a highly efficacious, affordable, short course treatment with not many side effects.24 This combination 
is now recommended by WHO Model List of Essential Medicines (MLEM) whereby piperaquine needs 
to be used in combination with dihydroartemisinin.24   
The global increase in the occurrence and transmission of malaria as well as resistance to known 
antimalarials emphasizes the need for more effective therapeutic agents. Emergence of resistant 
strains can be attributed to (i) expeditious reproduction period of the parasite leading to large 
populations of the mosquito and (ii) the miscellaneous use and misuse of antimalarials.25 Presently, 
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there are fourteen antimalarial drugs for curative treatment and six for prophylaxis on the current 
WHO MLEM .26 It is recommended that a combination of the drugs be taken in order to treat malaria 
caused by the P. falciparum parasite instead of monotherapy.26  
One popular drug in the treatment of malaria today is artemisinin (Figure 3) isolated by a from a plant 
called Artemisia annua.21 It is a sesquiterpene lactone which consists of a peroxide group that is 
believed to be an integral part of the drug’s mode of action. This drug was first identified with the aim 
of treating CQR strains of malaria. However, it has been proven that artemisinin has been the most 
successful in treating multi-drug resistant strains of P. falciparum malaria.12  
 
Figure 3: Structures (from left to right) of artemisinin, artesunate, artemether and dihydroartemisinin 
(DHA). 
There are currently two derivatives of artemisinin that are included in the WHO MLEM, specifically 
artesunate and artemether (Figure 3). These two, together with dihydroartemisinin (DHA) (Figure 3) 
are some of the most effective antimalaria drugs today.27 However, artesunate and artemether are 
prodrugs. This means that they are metabolized after administration, into the active DHA 
metabolite.21 What sets artemisinin apart from other antimalarial drugs is the fact that it does not only 
target the late stages of the parasite’s erythrocytic stage but also targets the early stages making it 
more efficacious.27 It works by significantly reducing the number of Plasmodium parasites in the 
infected patient’s bloodstream11 by killing the ring stage forms of the parasite in the intermediate host 
(human) during the early stages of infection.27 
As of 2016, artemisinin-based combination therapies (ACTs) have been declared as the first and 
second line (most effective) of treatment for uncomplicated cases of malaria as well as CQR malaria 
caused by P. vivax parasite.11 The WHO recommends the use of artemisinin-based combination 
therapy, i.e. by combining two drugs which have different MOA, in order to be more efficacious and 
less prone to resistance development.28 ACTs actually combine artemisinins (or one of its derivatives) 
with a partner drug.11 Determining which partner drug to pair with artemisinins depends on its 
pharmacokinetic properties.27 The artemisinin is employed to promptly decrease the number of 
parasites within three days of its course. Subsequently, the partner drug is responsible for clearing out 
the residual parasite in the bloodstream since it has a longer half-life.11 For this reason, the partner 
drug usually has a longer half-life, i.e. must be able to remove remaining parasites once artemisinins 
are expelled from the body.27  
The use of ACTs has significantly decreased the global malaria burden.12 Like many other antimalarial 
drugs, its limitation is onset of resistance. Resistance to ACTs is slow to develop but, it has been 
reported at the Thailand-Cambodia border in 2008.27 It is believed that this is not the first actual 
emergence of resistance. The first emergence may have been in 2001 prior to distribution of these 
drugs in Cambodia.27  
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Amodiaquine (Figure 4) is a drug usually used in combination with artesunate to make ACTs as 
recommended by WHO MLEM. Is it said that its MOA as well as side effects are similar to those of 
CQ.29 However, amodiaquine also modifies the DNA of the host. Even with their similarities, 
amodiaquine is actually a better therapeutic for uncomplicated cases of P. falciparum malaria 
compared to CQ in some parts where resistance has not developed, such as Africa, some parts of 
South America as well as Oceania.30 It has also been reported to be effective on some CQR strains. 
Notable side effects of amodiaquine have been reported such as leukopenia, hepatitis and 
agranulocytosis typically in cases where it was applied as prophylaxis.30 Due to its side effects, the use 
of amodiaquine as a prophylactic may be complicated particularly in pregnant women thus it is used 
for treatment only.   
Sulfadoxine (Figure 4) is a sulfonamide that was used for prophylaxis of malaria but was discontinued 
due to growing resistance. Sulfadoxine and pyrimethamine (Figure 4) have been used together since 
198121 for treatment of CQR malaria caused by plasmodium parasite.31 In combination, these drugs 
inhibit plasmodial forms of dihydrofolate reductase (DHFR) as well as dihydropteroate synthetase 
(DHPS) which are two of the most fundamental enzymes in the folate biosynthetic pathway of the 
parasite.32 Due to their synergistic effect, sulfadoxine and pyrimethamine are better when used in 
combination as opposed to single compounds.31 However, resistance started emerging following point 
mutations in the genes of these enzymes.32 In order to avoid treatment failure attributed to resistance, 
sulfadoxine and pyrimethamine is now used in combination with artesunate. Incorporating artesunate 
into this combination has a number of benefits including; helping reduce spread of resistance, prevent 
recurrence of malaria infection and hindering with transmittance of P. falciparum parasite to name a 
few.33 This combination is listed both for treatment and chemoprevention on WHO MLEM whereby: 
for treatment, it is recommended to be taken in combination with artesunate whereas for prophylaxis, 
amodiaquine is the preferred combination drug.26  
 
Figure 4: Structures (from left to right) of 4-amodiaquinoline, sulfadoxine and pyrimethamine. 
One evident factor to take note of is that none of the therapeutics mentioned above, or on the WHO 
MLEM, 2019, have metals incorporated into them.  
 
1.4.   Metal complexes as antiplasmodials 
 
Metals play a fundamental role in our everyday lives. With regards to human health, several metals 
are essential to vital biological processes. The periodic table contains a variety of metals thus it may 
have been intriguing for researchers to explore the applicability of other metals to living organisms.34 
To this day, cisplatin (Figure 5) is still a leading drug for treatment of different types of cancer. Metals 
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with similar chemical and physical properties to platinum, i.e. iridium, rhodium, ruthenium, osmium 
and palladium, termed platinum group metals (PGMs) are also of interest to researchers.35 It has been 
reported that complexes of these metals  have shown great activity as anticancer, antibacterial, 
antiplasmodial and antivirals agents.1,36, 37,38,39   
 
Figure 5: Structure of cisplatin. 
The first class of metal-based antimalarial drugs were developed by incorporating metals into the 
already existing drug CQ, i.e. ruthenium (Ru(II))-CQ binuclear complex (see 1.4.2a on Figure 6).2,40 
Ruthenium (Ru) was the metal chosen due to the extensive research that has been done on its 
application in various fields of medicine.2 Upon comparison to CQ, it was found that the Ru(II) complex 
was five times more potent against strains of P. falciparum and P. berghei (causative agent of malaria 
in rodents). Additionally, this drug showed excellent antiplasmodial activity against CQR strains.40 
Arene-Ru(II)-CQ complexes (see 1.4.2b on Figure 6) were also synthesized and these were found to 
have substantial activity against malaria.  
A ferrocene complex, ferroquine (FQ) however, demonstrated the greatest efficacy against CQ 
sensitive (CQS) and CQR strains of P. falciparum (Figure 6) in vitro and in vivo.2,41 The synthesis of this 
complex involves the insertion of a ferrocene moiety into the lateral chain of the known antimalarial, 
CQ.41 This great efficacy observed for FQ can be attributed to the fact that ferrocene is a very stable, 
highly lipophilic metal that has accessible redox states and low toxicity. To this day, ferroquine (FQ) is 
the most effective potential organometallic antimalarial currently in development. It is twenty times 
more potent than CQ with a similar MOA.2 For this reason, FQ is undergoing phase II clinical trials as 
an antimalarial drug.2 This guided research to the development of ruthenocene analogues of FQ. These 
complexes showed a similar MOA to that of FQ with good activities.2 
 
 
Figure 6: Structures of Ru binuclear complex (1.4.2a), arene-Ru(II)-CQ(1.4.2b) and ferroquine 
(FQ)(1.4.2c). 
The second metal to be considered for integration into CQ was gold (Au) (see 1.4.3a on Figure 7). 
These complexes displayed great potential as therapeutics for not only malaria, but other diseases as 
well.2 Following these results, Navarro, et al, developed new similar complexes with a PGM, iridium 
(Ir).42 The three compounds (Figure 7) were synthesized, characterized and their in vitro activity 
against the Plasmodium berghei strain of malaria was tested. Upon investigation by comparison of the 
complexes IC50 values, it was found that complex 1.4.3c showed the highest activity whereas 
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complexes 1.4.3b and 1.4.3d showed lower activity. With an IC50 value of 59 nM, complex 1.4.3c 
showed a slight increase in activity in comparison to CQ.42 In contrast, complex 1.4.3b (72 nM) and 
1.4.3d (126 nM), were not as active.  These results further validates that introducing a metal into an 
inorganic scaffold has the potential to increase its activity.1,2,42  
 
 
Figure 7: Structures of gold complex (1.4.3a) and CQ derivatised complexes (1.4.3b-d).42 
Rhodium (Rh) has not always been the metal of choice in the field of medicine, it is only recently that 
researchers have developed an interest in it. One of the reasons for this sudden interest in Rh is due 
to the variety of biological and chemical properties that are adjustable. Developing Rh complexes as 
antimalarials also offers varying MOAs and diversifies the range of said drugs.43  The earliest example 
of an antimalarial Rh complex was also reported by Navarro et al in 1996 where they synthesized Rh 
and Ru complexes of CQ and tested their activity against Plasmodium berghei (Figure 8).44   
 
Figure 8: Structure of RhCl(COD)(CQ) (1.4.3e) and  [RuCl2(CQ)]2 (1.4.3f).44 
From this study, it appeared that both complexes had inhibitory action with complex 1.4.3f having 
similar activity to CQ diphosphate and complex 1.4.3e being five times more active. Since complex 
1.4.3e showed better activity, further investigations were done against CQ resistant strains of 
Plasmodium falciparum. Reportedly, this incorporation of Ru also led to a 2-5 fold increase in activity 
without acute toxicity.44 
Ekengard et al. reports the synthesis of N,N and N,O chelating chloroquine derivatives of  iridium and 
rhodium complexes.45 Electronic variation of the salicylaldimine (N,O) ligands in the para position of 
the salicyl moiety was also explored. This was done by introducing H, F, Cl, Br, I, NO2, OMe and t-Bu to 
study the effect on the antimalarial activity of the resulting ligands and complexes. The in vitro 
biological activity of the ligands and complexes were tested against two strains of the P. falciparum 
parasite, i.e., CQS strain, NF54, and the CQR strain, Dd2, with CQ and artesunate as references. 
Ruthenium analogues of these ligands that had been previously reported showed that incorporating 
the ruthenium para-cymene moiety showed poor activity against the malaria strains.46 Iridium 
analogues of these complexes on the other hand showed moderate activities whereas the N,N 
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derivatives showed inactivity. It was found that the salicylaldimine rhodium complexes with electron 
withdrawing groups on the para position of the salicyl moiety exhibited the best activities against both 
strains. Additionally, complexes 1.4.4.3e (Rh) (IC50 = 0.016 ± 0.002 𝜇M), 1.4.4.3f (Rh) (IC50 = 0.020 ± 
0.006 𝜇M) and 1.4.4.3g (Rh) IC50 = 0.018 ± 0.006 M (Figure 9) showed better activity than CQ (IC50 = 
0.027 ± 0.011 𝜇M) against the CQS NF54 strain, however, not as active as artesunate (IC50 = <0.005 
𝜇M). The exceptional activity of complex 1.4.4.3e (Rh)  was reported to have the best antiplasmodial 
activity of complexes without a ferrocene moiety.45 
 
Figure 9: Structure of ligands and complexes reported by Ekengard.45 
Seven iridium complexes of 7-chloroquinoline-1,2,3-triazole hybrid ligands were synthesized, the 
ligands’ and complexes’ in vitro biological activity against CQS NF54 P. falciparum strain(Figure 10).47 
The in vitro assays showed that all the ligands were not highly potent against the NF54 P. falciparum 
strain (IC50 = 9.97 – 28.02 𝜇M). Incorporation of the iridium metal shows significant improvement in 
activity where complex 1.4.5.2 was over a 100-fold more active than its parent ligand 1.4.5.1f. 
Complexes showed activity in the order 1.4.5.2 > 1.4.5.3a > 1.4.5.3e > 1.4.5.3b > 1.4.5.3d > 1.4.5.3c > 
1.4.5.4. This trend in activity showed that the introduction of the hydrophobic R groups does not have 
a significant role in the resulting potency against the NF54 P. falciparum parasite strains. The 
monodentate coordinated complex 1.4.5.4 showed the least activity (IC50 = 48.45 ± 1.73 𝜇M) 
suggesting that stability provided by the coordination of the metal in a bidentate fashion as seen for 
complexes 1.4.5.3a-1.4.5.3f plays an important role in the efficacy of the complex against NF54 
malarial strains. Complexes that showed higher activity against NF54 were also tested against CQR K1 
strain, activity was found to be in the IC50 range of 0.13 – 3.06  𝜇M. Analysis of the resistant indices of 
the complexes indicated trace existence of resistance. The in vitro cytotoxicity of the complexes 
against Chinese Hamster ovarian cancer cell line was also evaluated using emetine as a positive 
control. No cytotoxicity was displayed by the complexes. β-Haematin inhibition studies were 
conducted to investigate the potential MOA of this class of complexes using 1.4.5.1g, 1.4.5.3d and 
1.4.5.3f with antimalarial drug CQ as a control. The complexes did show  β-haematin inhibition, 
however, not to the same degree CQ.47 




Figure 10: Structure of 7-chloroquinoline-1,2,3-triazole hybrid ligands and ruthenium complexes 
reported by Melis et al.47  
Metal complexes of other existing clinical drugs for potential malaria treatment have also been 
synthesized, these include quinoline derivatives, i.e., mefloquine, amodiaquine and primaquine. 
Moreover, several metals were investigated in conjunction with Rh, Cu, Fe, Au, Ni, Pt, etc.  It was 
discovered that these modified drugs could potentially be the next generation of therapeutics.2  
Iridium, rhodium and ruthenium pyridyl- and quinolyl imino half sandwich organometallic complexes 
containing the drug sulfadoxine were synthesized and their antiparasitic activity evaluated by Chellan 
et al.48 (Figure 9). The in vitro antiplasmodial activity against various parasite strains and 
Mycobacterium tuberculosis bacteria were evaluated. The parasite strains included three P. 
falciparum strains, i.e., 3D7 CQ sensitive strain, CQR strain, Dd2, as well as NF54 (sexual late stage 
gametocyte (LSG)), and, Trichomonas vaginalis. It was reported that several complexes exhibited 
efficacy in the sexual LSG assay against P. falciparum strains. However, upon investigation of 
sulfadoxine and other known antimalarial drugs (pyrimethamine and CQ) in the same assays, no 
evidence of any inhibitory action was found, they were all inactive.  
Researchers have shown interest in benzimidazole and its derivatives due to its antiplasmodial activity 
against antimalarials49 as well as antitumor50 and antiretroviral activity51. For this reason, it is 
recognized as a promising organic scaffold in medicine. A study on the synthesis, characterization and 
in vitro biological studies of substituted 2-phenylbenzimidazoles (H, Cl, CH3 and CF3) ligands and 
iridium, rhodium and ruthenium complexes was carried out by Rylands et al(Figure 11).52 The 
antiplasmodial activity of the ligands and complexes were evaluated against P. falciparum NF54 CQS 
strain. The derivatized ligands 1.4.6a – 1.4.6d showed weak antimalarial activity (IC50 = 17.66 – 22.32 
𝜇M) against the NF54 strain.  
 




Figure 11: Structures of 2-phenylbenzimidazoles ligands and complexes reported by Rylands et 
al.52 
Incorporation of the metals onto the substituted 2-phenylbenzimidazole ligands significantly 
improved their antiplasmodial activity resulting in a low range of inhibitory concentrations of 0.12 – 
5.17 𝜇M. It was observed that the substituents did not seem to have a great impact on the 
antiplasmodial activities of the complexes. Cyclometallated complexes showed activity in the order 
Ru>Ir>Rh across all the series of complexes. As a result, further screening of the ruthenium and iridium 
complexes was carried out against the CQR P. falciparum strain, K1, which is also resistant to multiple 
other drugs. Activity of the complexes against this strain showed the ruthenium analogues to be twice 
more active than the iridium complexes. A loss of activity observed against K1 strain compared to 
activity against NF45 was attributed to reduced ability to target the resistant strains. Cytotoxicity 
studies of the hydrogen substituted ruthenium (IC50 = 50.92 ± 0.81 𝜇M) and iridium complexes (IC50 = 
20.71 ± 0.23 𝜇M) performed against the Chinese Hamster Ovarian (CHO) cells displayed low toxicity. 
In an attempt to investigate the potential MOA, the -haematin inhibition studies did not show any 
activity up to 500 𝜇M implying a different MOA. The activity of these complexes, their relatively low 
cytotoxicity and resistance indices (RI) indicates their promising application as new antimalarials, thus 
further studies are required for this class of compounds.52  
 
The synthesis and study of 7-nitrobenzoxadiazole (NBD) ligands and N,N ruthenium half-sandwich 
complexes as antiplasmodials were reported by Milheiro and co-workers (Figure 12).53 The in vitro 
antiplasmodial activity of the complexes was evaluated against the blood stage CQS 3D7-GFP, CQR 
Dd2 as well as artemisinin-resistant IPC5202 P. falciparum strains with CQ, DHA and primaquine used 
as a reference. Thereafter, the antimalarial activity of the complexes against the human hepatic cells, 
HepG2, their relative cytotoxicity and theirs SI’s were evaluated. Ruthenium complexes 1.4.7a – 1.4.7c 
(IC50 = 7.69-12 nM) exhibited high potency against the CQS 3D7-GFP strain of P. falciparum parasites 
in the order 2>1>3 whereas 1.4.7d and 1.4.7e (IC50 = 219 ± 62 nM and IC50 = 139 ± 54 nM respectively) 
were weakly active. Low potency was observed for all complexes against CQR Dd2 strains, however, 
the activities were still better than that of CQ. 1.4.7a-c also displayed better activity in comparison to 
1.4.7d and 1.4.7e against artemisinin-resistant IPC5202 P. falciparum strains, even so, lower RIs were 
obtained for 1.4.7d and 1.4.7e. The bulkier pentamethylcyclopentadientyl moiety of 1.4.7c compared 
to the less bulky cyclopentadiene of 1.4.7b did not pay any significant role in the activity against the 
P. falciparum strains even with increased lipophilicity. A measure of the complexes’ cytotoxicity 
against the human hepatic cells, HepG2, revealed that complexes 1.4.7a-c were not highly toxic. It was 
reported that these complexes are amongst the most promising cyclometallated antimalarials to 
date.53 




Figure 12: Structure of N,N ruthenium half-sandwich complexes. 53 
 
1.5.   Summary 
 
Reports of widespread reduced efficacy of current drugs due to the growing resistance of malaria 
parasites is one of the biggest issues in the management of the malaria endemic. It is thus important 
to design and study new compounds for the treatment of malaria. For many years, the discovery and 
development of antiplasmodials against malaria was predominantly focused on the derivatisation of 
known antimalarials in an effort to overcome resistance. Extensive studies of the biological activity of 
CQ derivatized metal complexes aimed at discovering new and effective antimalarials has been done. 
These efforts have resulted in the discovery of ferroquine, a drug candidate which has reached Phase 
II clinical trials. Recently, increasingly more research has gone into the development of metal 
complexes containing organic scaffolds as several reports have observed an improvement in their 
biological activity against malaria parasites once incorporated with a metal. Incorporating a metal into 
and organic scaffold results in complexes with great properties as they include both an organic 
pharmacophore as well as a metal offering different properties. The nature of the cyclometallated 
complexes allows for adaptations that can improve the compound’s activity and its physicochemical 
properties. Thus, this area of research continues to thrive and in this thesis we discuss the study of 
dipyridylamino complexes of the PGMs Ru(II), Ir(III) and Rh(III) as antiplasmodials. 
2,2-Dipyridylamine, is a versatile ligand and it’s chlorido and iodide complexes  with ruthenium,54 
rhodium and iridium55 have been evaluated for in vitro biological activity against a human ovarian 
cancer cell line, A2780. No data has been reported on their applicability as antiplasmodials. In this 
thesis the synthesis, characterization and biological activity of the same six complexes as well as six 
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1.6.   Aims and objectives: 
1.6.1. Aims 
The aim of this project was to synthesize and characterize a library of iridium (Ir), rhodium (Rh) and 
ruthenium (Ru) half-sandwich organometallic complexes from 2,2-dipyridylamine (dpa), where the 
complexes were isolated with either a PF6- counterion or NO3- counterion. The intention was to 
observe whether the counterion will influence biological activity. The aqueous solubility and 
interaction with water and DMSO of the ligand and complexes would then be studied, and they would 
be screened for in vitro biological activity against malaria strains. 
1.6.2. Objectives: 
1.6.2.1. Twelve cationic N,N’-chelated half-sandwich organometallic complexes of 2,2-dipyridylamine 
were synthesized according to scheme 1 below. C1-C6 were synthesized and underwent 
counterion exchange to PF6-. C7-C12(novel) also underwent a counterion exchange to NO3-.  
 
Scheme 1: Synthetic route for the synthesis of complexes C1-C12. 
1.6.2.2. Characterization was done using the following analytical techniques; infrared spectroscopy 
(ATR-FTIR), nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), high 
performance liquid chromatography (HPLC), cyclic voltammetry (CV) and single crystal X-ray 
diffraction (XRD) discussed in Chapter 2.  
1.6.2.3. The aqueous solubility of the complexes was studied using turbidimetric assay which will we 
discussed in detail in chapter 3.  
1.6.2.4. The hydrolysis studies of the complexes was done under biologically relevant conditions. The 
results of this study will be analysed in Chapter 3. 
1.6.2.5. In vitro biological activity of the ligand and complexes against CQS 3D7 strain and the drug 
sensitive NF54 strain of the P. falciparum parasite was investigated. The inhibitory 
concentrations of these compounds are discussed in detail in chapter 3. 
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Synthesis and characterisation of complexes C1-C12 
2.1.  Introduction 
The emergence of resistant plasmodium strains to currently used antimalarial drugs has brought about 
extensive research in finding new chemotypes effective in treating malaria. As discussed in Chapter 1, 
one area of drug discovery in the field of malaria is focused on incorporating metals into already 
existing drugs in an attempt to improve their efficacy since the most effective current antimalarial 
being chloroquine, has proven to be less effective and even ineffective in some parts of the world.123 
Incorporating metals, especially PGMs, into organic pharmacophores has proven to have an effect on 
the ligand’s antiplasmodial activity, i.e., improving its efficacy 4,5,6, etc. The ligand 2,2’-dipyridylamine 
(Dpa), an organic pharamacophore, is a metal complexing agent that is normally used as a bidentate 
nitrogen donor ligand. Dpa has been employed in various fields of research including  catalysis, 7,8 and 
in medicinal chemistry. Ŝtarha et al. studied their in vitro cytotoxicity against the A2780 ovarian 
carcinoma cells.9,10 They reported the synthesis and study of ruthenium(Ru) para-cymene (p-cym) half 
sandwich organometallic complexes with a PF6- counterion and the effect of replacing their chlorido 
ligand with different halogenido ligands(see Figure 2.1).10 This work was later expanded with 
iridium(Ir) and rhodium(Rh) cyclopentadienyl (Cp*) bidentate metal complexes9 (see Figure 2.1). It 
was found that the iridium-chlorido (Ir(η5-Cp*)(dpa)Cl]PF6), iridium-iodido (Ir(η5-Cp*)(dpa)I]PF6)  and 
rhodium-iodido (Rh(η5-Cp*)(dpa)I]PF6)  complexes were active against the A2780 human cancer cell 
line while the rhodium-chlorido (Rh(η5-Cp*)(dpa)Cl]PF6), ruthenium-chlorido [Ru(η5-(p-
cymene))(dpa)Cl]PF6 and ruthenium-iodido [Ru(η5-(p-cymene))(dpa)I]PF6 complexes were inactive.9,10  
 
Figure 2.1: Dpa complexes reported by Ŝtarha.9,10 
This chapter focuses on the synthesis and characterization of twelve iridium, rhodium and ruthenium 
half- sandwich organometallic complexes of the ligand Dpa. Six of them (C1-C6) have the PF6- 
counterion and were previously reported by Ŝtarha et al., and the other six (C7-C12) have a NO3- 
counterion. A previous study of cationic metal complexes bearing a different counterion shows an 
effect on several of its properties including solubility, kinetic stability as well as its bioavailability.11 
Additionally, varying the halogenido ligand from chlorido to iodido also showed an increase in 
bioactivity.12 It has been reported that exchanging a chlorido ligand for an iodido ligand has as effect 
on the polarization12 of the complex as well as its redox potential.13,14 The replacement results in an 
increase in the positive charge polarization on the metal complex, where chlorido is less positive than 
iodido. This has resulted in more potent complexes that are also more selective.12 Thus, we wished to 
investigate whether changing the counterion for these PGM complexes of Dpa would also affect its 
properties and antimalarial potency. In this chapter, the synthesis and characterisation of Ir(III), Rh(III) 
and Ru(II) complexes with either a PF6- or  NO3- counterion respectively will be discussed. 
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2.2. Results and Discussion  
2.2.1. Synthesis of the complexes 
Dpa is a bidentate ligand that chelates to a metal using the nitrogen atoms of the pyridyl rings.15 
Cationic PF6- organometallic complexes of Ir(III), Rh(III) and Ru(II) have all been previously synthesized 
and reported in literature.8-10 The organometallic complexes C1-C12 were made following an adapted 
microwave reaction reported by Ŝtarha, et al. according to Scheme 2.1.10 Dpa is combined with 
appropriate metal dimer to produce the cationic Cl- complexes. These are not isolated and are simply 
carried to the next step. To displace the Cl-/I- counterion, each complex is stirred in methanol with 
ammonium hexafluorophosphate (C1-C6) or ammonium nitrate (C7-C12) in order to yield the final 
product. The complexes C1-C6 are isolated as red, orange or yellow crystalline powders in moderate 
to good yields. They were found to be soluble in acetone, acetonitrile, DCM, DMSO and methanol 
(with heat). Complexes C7-C12 on the other hand were isolated as yellow or orange crystalline 
powders in moderate to good yields and are soluble in water, acetonitrile, DCM, DMSO and methanol 
(with heat). The synthesis of the starting material, i.e. metals dimers [Ir(Cp*)Cl2]2, [Ir(Cp*)I2]2, 
[Rh(Cp*)Cl2]2, [Rh(Cp*)I2]2, [Ru(p-cymene)Cl2]2 and [Ru(p-cymene)I2]2   were adapted from reported 
methods.16,17 
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2.2.2. Characterisation of complexes C1-C12 
FTIR was used to confirm the coordination of the metals to Dpa. The complexes C1-C6 were 
characterized with reference to the literature.10,11 The FTIR spectra of complexes C1-C6 were very 
similar. A summary of distinctive bands of complexes C1-C6 are summarised on Table 2.1 below. A 
strong band between 827-832 cm-1, distinctive of the PF6- stretch, was observed for complexes C1-C6 
signifying successful exchange of the Cl-/ I- counterion. The C=N stretching vibrations were observed 
between 1624-1628 cm-1, a shift of about 33-37 cm-1 from 1591 cm-1 of the Dpa (see Figure 2.2 below). 
This is attributed to the fact that electron distribution in the pyridyl rings has changed. Electron density 
is being pulled away from the pyridine rings by the electropositive metal thus making the C=N bond 
stronger and consequently shorter. Strengthening of the other bonds in the pyridine ring can also be 
observed in the slight increase in frequency for C-N aromatic stretches from 1139 cm-1 for the ligand 
to 1158-1162 cm-1 for the complexes. Additionally, this proves that coordination took place through 
the N atoms. The C-H aliphatic stretches of the cyclopentadienyl ring (Cp*) and para-cymene (p-cym) 
were observed for complexes C1, C4, C5 and C3 between 2918-2984 cm-1 and not observed for C2 and 
C6, however, these were detected using proton NMR which will be discussed. No significant 
differences between the spectra for the chlorido (C1-C3) versus iodido (C4-C6) complexes was 
observed. 
Table 2.1: Significant IR frequencies for Dpa ligand and hexafluorophosphate (PF6-) complexes. 
Complex  (PF6) 
(cm-1) 







(Cp*/ p-cym) (cm-1) 
Dpa  1591  1139  
C1 832 1628 1472 1162 2918, 2984 
C2 823 1625 1467 1161 (not visible) 
C3 830 1625 1465 1161 2979 
C4 829 1626 1471 1161 2980 
C5 827 1624 1469 1159 2980 
C6 834 1626 1467 1158 (not visible) 
 




Figure 2.2: FTIR (ATR) spectra of Dpa (top) and C1 (bottom). 
 
From the IR spectra obtained for complexes C7-C12, the complexation and counterion exchange 
appears to have taken place. This is observed at wavelengths 1299-1317 cm-1 and 764-771 cm-1 where 
the nitrate symmetric and asymmetric stretch absorptions, respectively, are found (see Table 2.2 
below). A clear shift of the C=N stretch is also observed for the nitrate complexes as indicated on Table 
2.2, suggesting coordination through the nitrogen atoms of the pyridine rings. Further evidence of 
metalation is the emergence of the C-H bending and stretching bands attributed to the Cp* and p-
cymene moiety. 
Table 2.2: Significant IR frequencies for Dpa ligand and nitrate (NO3-) complexes). 












Dpa   1591  1139  
C7 770 1310 1637 1470 1157 2916, 2958 
C8 771 1311 1634 1467 1156 2916, 2953 
C9 766 1315 1634 1469 1158 2963 
C10 766 1299 1625 1470 1154 2909, 2953 
C11 768 1301 1623 1468 1153 2956 
C12 764 1317 1623 1466 1155 2971 
 
The 1H NMR spectra of the ligand (Dpa) and complexes C1-C12 were all run in methanol-d4 (summary 
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complexes. This is because the amino proton is readily and rapidly exchangeable for the protons of 
the deuterated methanol which makes it difficult to detect. Due to symmetry, all the peaks in the 
aromatic region are assigned to two protons of each pyridyl proton at the same positions. For 
complexes C1, C2, C4, C5, C7, C8, C10 and C11, a singlet at 1.46-1.63 ppm integrated for 15 protons, 
H19-H23, allocated to the methyl groups of the Cp* moiety was observed.  The shift in resonances 
attributed to the pyridyl ring protons for the complexes compared to the Dpa ligand confirm 
metalation. For all complexes, a downfield shift is observed for the protons of the pyridyl rings that 
are ortho (H2 and H10), meta (H3 and H11) and para (H4 and H12) to the pyridyl nitrogens (indicated by 
green arrows in Figure 2.3).  As previously mentioned, coordination of the electron-withdrawing 
metals to the ligand results in electron density being donated by the pyridine rings to the metal centre 
and resulting in the protons being less shielded. For the protons on the carbons in the meta position 
to the pyridyl nitrogens, a downfield shift is noted for H3 and H11 and an upfield shift for H5 and H13. 
Although in similar positions, these four protons experience different electron environments. The 
amine is an ortho and para directing electron-donating group and is situated in the ortho position 
relative to the protons H5 and H13. As a consequence, these protons are being more shielded due to 
its electron donating ability. The same phenomenon is expected for H3 and H11 since they are 
positioned para to the amino group. However, their position relative to the pyridyl nitrogens, where 
the metal is chelated, has a stronger effect on their shielding. The de-shielding effect from electron 
density being pulled away from the pyridyl rings by the metal surpasses the shielding effect resulting 
from the para directing amine. This was expected and it is consistent with literature reporting on 
complexes C1-C6.9,10  Protons H2 and H10 resonate as a doublet since they couple to protons H3 and H11 
(see 1H spectrum of C1 on Figure 2.4). Two triplets attributed to protons H4 and H12, and H3 and H11 
resonate at 7.96-8.03 ppm and 7.25-7.34 ppm respectively, as a result of coupling to each other and 
to their neighbouring protons H5 and H13, and H2 and H10. The doublet resonating at 7.28-7.47 ppm is 
assigned to H5 and H13 since they only couple to H4 and H12. The resonances for protons H5 and H13, 
and H3 and H11, which should be observed as a doublet and a triplet respectively, overlap and appear 
as a multiplet between 7.18-7.34 ppm for the Rh- and Ru-chlorido complexes C2, C3, C8, and C9. The 
1H spectra of C3, C6, C9 and C12 displays signals for all protons of the para-cymene moiety (Figure 
2.5). 
Table 2.3: 1H NMR shifts (ppm) of the Dpa ligand and the PF6- complexes C1-C6 in methanol-d4. 
 











H2 and H10 (d) 8.20 8.43 8.44 8.63 8.65 8.67 8.80 
H4 and H12 (t) 7.66 7.95 7.98 7.92 7.91 7.98 7.89 




7.30 7.28 7.16 













H24 and H27 (d) 
  
    5.66     5.67 
H25 and H26 (d)     5.56     5.61 
H31 (sep)     2.61     2.65 
H29 (s)     2.09     2.22 
H32 and H33 (d)     1.22     1.22 
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Table 2.4: 1H NMR shifts (ppm) of the Dpa ligand and the PF6- complexes C7-C12 in methanol-d4. 
 











H2 and H10 (d) 8.20 8.43 8.45 8.63 8.66 8.66 8.81 
H4 and H12 (t) 7.66 7.96 8.00 7.93 7.93 7.98 7.89 




7.30 7.31 7.19 





HCp* (19-23)   1.47 1.50  1.55 








H24 and H27 (d) 
  
    5.67     5.68 
H25 and H26 (d)     5.57     5.62 
H31 (sep)     2.62     2.65 
H29 (s)     2.10     2.22 
H32 and H33 (d)     1.23     1.22 
 
Figure 2.3: Aromatic region of the overlapped 1H NMR spectra of Dpa (red) and C1 (blue) in 
methanol-d4 (CD3OD).


















Figure 2.5: 1H NMR spectra of C3 in methanol-d4. 
The para-cymene moiety shows seven peaks attributed to fourteen protons in different chemical 
environments for C3, C6, C9 and C12. The protons of the tertiary carbon of the isopropyl group for the 
para-cymene moiety was expected to resonate as a septet since it couples to protons H32 and H33 
contributing three protons each: 
For I = 6, the N(number of neighbouring protons) + 1 rule eludes that: 
multiplicity = 6 + 1 = 7 signals (septet) 
C3 has the proton H31 signal resonating at 2.61 ppm as a quintet with weak intensity (Figure 2.5). 
However, a septet is observed for complexes C6, C9 and C12. In the 1H spectra of C3, C6, C9 and C12, 
two doublets at 5.66-5.68 ppm and 5.56-5.62 ppm are assigned to nuclei H24 and H27, and H24 and H27 
respectively.  A singlet at 2.09-2.22 ppm integrated for 3 protons belongs to the methyl of the p-
cymene moiety, H29. The protons H32 and H33 of the isopropyl group resonate as doublets at 1.22-1.23 
ppm as they couple to H31. A comparison of the chlorido complexes (C1, C2, C3, C7, C8 and C9) to their 
respective and iodido complexes (C4, C5, C6, C10, C11 and C12) reveals that the protons ortho to the 
pyridyl nitrogen (H2 and H10) are more deshielded for the iodido complexes. This is expected since 
iodine is higher in the nephelauxetic series than chlorine. Therefore, this generates a stronger pull on 
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For the purpose of further substantiating successful metal coordination, 13C NMR of the novel nitrate 
complexes was conducted, 13C NMR was not done for known PF6- complexes C1-C6. From the spectra 
acquired, all carbons were assigned (see Table 2.4). The 13C NMR of all complexes were recorded in 
methanol-d4. The Ir and Rh complexes C7, C8, C10 and C11 have the carbons ortho to the two pyridyl 
protons (C6, C8, C2 and C10) as the most deshielded, with the quaternary carbons being more downfield 
as demonstrated in Figure 2.7 with the spectra of C9. Other pyridyl carbons all resonate in the aromatic 
region as singlets. The carbons of the Cp* moiety resonate at different positions (see Figure 2.6), those 
of the five-membered ring resonate at a higher frequency (89.55-98.50 ppm) whereas the methyl 
carbons are in the lower aliphatic region between 8.74-9.85 ppm. As seen for the proton NMR, the 
para-cymene moiety of complexes C9 and C12 gives rise to more peaks in the spectra (see Figure 2.7). 
The isopropyl and methyl group on the para-cymene creates a different chemical environment for the 
carbons on the benzene ring. Two quaternary carbons, C28 and C30, are seen as weak signals resonating 
at 101.34-100.81 ppm and 108.13-109.77 ppm respectively. Methyl carbon, C29, is observed at lower 
frequencies (18.36 and 19.59 ppm) in the aliphatic region whereas the isopropyl carbons resonate at 
a higher frequency of 22.34 and 22.43 ppm for ruthenium complexes C9 and C12.  
 
Table 2.4: 13C NMR shifts (ppm) of the NO3- counterion complexes C7-C12 in methanol-d4. 












C6,8  153.62 153.81 155.72 156.02 158.81 
C2,10  153.37 152.71 154.45 153.80 154.39 
C4,12 142.38 142.21 141.77 142.11 141.58 
C3,11 122.2 122.06 120.66 121.80 120.32 




 Cp* (14-18) 89.55 97.95  98.50  








C30   108.13  109.77 
C28   101.34  100.81 
C24,27   86.83  87.50 
C25,26   85.21  84.92 
C31   32.18  32.63 
C32,33   22.34  22.43 
C29   18.36  19.59 
 
As seen for the 1H NMR spectra discussed above, the same phenomenon was observed when 
comparing the chlorido complexes (C8 and C9) to their respective iodido complexes (C11 and C12).  
The carbons ortho to the pyridyl nitrogen (C6, C8, C2 and C10) were found to be more deshielded for 
the iodido complexes. A comparison of differences in shifts between PF6- complexes, C1-C6, and NO3- 
complexes C7-C12 showed that the complexes had very similar shifts, very small inconsistent 
differences were be observed and could not be rationalised. 
 




Figure 2.6: 13C NMR spectra of C8 in methanol-d4.  
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Mass spectra of the nitrate complexes C7-C12 were collected using the positive electrospray ionisation 
(ESI) mode. The base peaks corresponding to the metal cation species([M]+) with loss of the NO3- 
counterion were observed for each complex (see Table 2.5).  
Table 2.5: m/z values of the base peaks seen in the mass spectra of the nitrate complexes C7-C12 in 
the positive ionisation mode. 
Complex m/z ESI+ 
C7 534.1286 [Ir(η5-Cp*)(dpa)Cl]+ 
C8 444.0718 [Rh(η5-Cp*)(dpa)Cl]+ 
C9 442.0929 [Ru(η5-(p-cym)(dpa)Cl]+ 
C10 626.0641 [Ir(η5-Cp*)(dpa)I]+ 
C11 538.073 [Rh(η5-Cp*)(dpa)I]+ 
C12 533.9994 [Ru(η5-(p-cym)(dpa)I]+ 
 
Single crystals of C1 and C2 were grown from a solution of acetone and diethyl ether and single crystals 
of complexes C7 and C9 were grown from a solution of methanol and diethyl ether. The crystal 
structures were solved by single crystal X-ray diffraction and had not been reported at the time of the 
thesis write-up. The [Ir(η5-Cp*)(dpa)Cl]PF6 complex C1 crystallised in the orthorhombic space group 
P212121 whereas the [Ir(η5-Cp*)(dpa)Cl]NO3 complex C7 crystallised in the monoclinic P21/c space 
group. Rh complex C2, crystallised similar to C1 in the orthorhombic space group P212121. The Ru-
nitrate complex C9 crystallised in the triclinic P-1 space group with a molecule of water.  
Half-sandwich organometallic complexes are known to adopt the pseudo-octahedral piano-stool 
geometry, which was also the case for complexes C1, C2, C7 and C9.5,18,19  A summary of the recorded 
bond lengths and angles is tabulated below in Table 2.6 and Table 2.7. Bond lengths and bond angles 
were calculated using Mercury 4.3.1. software. Centroids in Table 2.6 and Table 2.7 were created for 
the pentamethylcyclopentadienyl and para-cymene rings using Mercury 4.3.1. software. The 
centroidal bond lengths and bond angles between the centroid and adjacent angles was calculated 
using Mercury 4.3.1. thus standard errors could not be obtained for those values. The centroids are 
not included in Figure 2.9 above. Structurally similar complexes were reported by Liu et al. where 
iridium is cyclometallated to 2-phenylquinoline and has a PF6- counterion is used for comparison.20 
Reported complex,20 and complex C1 were both found to have crystallized in the same space group. 
The bond length between Ir and the centroid of Cp* of complex C1 was found to be 1.775Å which was 
comparable to that of the reported complex which was 1.829 Å. Complex C7, the nitrate analogue of 
C1, also had a comparable metal-centroid (Ir- Cp*) bond length of 1.782Å to C1 and it was also 
comparable to the reported complex, a comparison is made to evaluate whether the complexes had 
generally accepted values in comparison to known similar complexes. This was also observed for the 
metal-halide (Ir-Cl) and metal-nitrogen (Ir-N1/ Ir-N9) bonds for complexes C1 and C7 which were in 
the range 2.395(7)-2.936(3)Å and 2. 017(2) -2. 084(8) Å respectively. The bond lengths of complex C2 
were found to be in agreement with those of complexes C1 and C7. The crystal structures show that 
the metals coordinate through the nitrogen atoms N1 and N9. The crystal structure of complex C3 of 
the form [Ru(η5-(p-cymene))(dpa)Cl]PF6, that is similar to complex C9 was reported by Romain et al 
and was used for comparison.8 The Ru- Ccentroid = 1.677Å, Ru-Cl= 2.422(4) Å, and the N-C bonds in the 
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range 1.345(2)-1.38(2) Å are in agreement with reported values in literature of a similar complex. The 
structure of the crystals are shown in Figure 2.8 below, the counterions and hydrogen atoms have 
been omitted for clarity. From the results obtained, the complexes prove that the intended complexes 
were synthesized successfully. A comparison to reported compounds which are structurally similar 


























Figure 2.8: Crystallographic structure of complexes C1, C2, C7 and C9. Hydrogen atoms, solvents and 
the counterions have been omitted for clarity. Ellipsoids at 50% probability. 
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Table 2.6: Bond lengths for complexes C1, C2, C7 and C9 (Ccentroid of Cp* ring). 
 Complexes 
PF6- NO3- 








M- Ccentroid 1,775 1.779 1.782 1.677 
M-X 2.396(3) 2.3928(6) 2.395(7) 2.422(4) 
M-N1 2.086(9) 2.094(2) 2.086(2) 2.107(1) 
M-N9 2.084(8) 2.093(2) 2.107(2) 2.093(1) 
N1-C2 1.370(1) 1.342(2) 1.359 (3) 1.358(2) 
N1-C6 1.360(1) 1.356(3) 1.349(3) 1.345(2) 
N9-C8 1,350(1) 1.347(3) 1.350(3) 1.346(2) 
N9-C10 1.360(1) 1.353(3) 1.361(3) 1.363(2) 
 
Table 2.7: Bond angles for complexes C1, C2, C7 and C9. 
 Complexes 
PF6- NO3- 








N1-M-N9 83.7(3) 84.10(7) 83.28(7) 84.54(5) 
N1-M-X 86.6(3) 89.32(5) 88.08(5) 86.74(3) 
N1-M-Ccentroida 128.62 128.08 128.77 129.27 
N9-M-X 87.3(2) 88.26(5) 88.45(5) 87.11(3) 
N9-M-Ccentroida 128.79 127.82 127.10 126.94 
X-M-Ccentroida 127.04 125.72 126.97 127.64 
a Distances and angles were calculated using Mercury software version 4.3.1. 
 
2.2.3. DMSO interaction studies 
The aprotic solvent, DMSO, is known to interact with some metal complexes which could result in 
dissociation of a ligand from the complex or cleavage of metal-halide bonds.21 This is especially 
important to study since DMSO is used to prepare the compound stock solutions prior to use in in vitro 
biological assays.  In order to investigate whether any interaction between the complexes and DMSO 
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takes place, a study using 1H NMR was conducted. This was done by preparing a sample of each 
complex in DMSO-d6 and immediately running 1H NMR and again after 24 hours.   For these complexes, 
an interaction could occur with the metal whereby DMSO-d6 displaces the Cl/I ligand. On condition 
that this occurs, a change would be observed between a NMR spectrum run immediately and one run 
after 24 hours as the chemical environment around the metal would be different with DMSO-d6 
coordinated to it. The two spectra of each complex were compared by overlapping the spectra run at 
0 hours and that run after 24 hours. No differences in the spectra was observed (see a fragment, i.e., 
pyridyl protons region, of overlapped spectra for C3 on Figure 2.9). However, whether interaction 





Figure 2.9: Overlapped pyridyl protons fragment of the 1H NMR spectra of C3 (red: 0hrs, blue: 24hrs). 
A study reporting the synthesis of complexes C3 and C6 conducted a similar study by running 1H NMR 
in DMSO-d6 immediately after preparing the sample and again after 48 hours They also reported that 
no changes were detected from which they concluded that no interaction takes place.22 Before it can 
be concluded that the Dpa complexes are stable in DMSO-d6 even after standing for 24 hours at room 
temperature, further investigations were necessary. A DMSO titration study was done on complex C2. 
A 1mM stock solution of C2 was prepared in dichloromethane (DCM). In a quartz cuvette, 1ml of the 
stock solution was transferred and a 4mM stock solution of DMSO was added in small increments 
from 1-100 equivalents. After each addition, the UV-Vis spectrum of the sample was obtained 
between 220-1000 nm. This was performed in order to determine whether any interaction does occur, 
and if so, after how many equivalents of DMSO added would the reaction reach its endpoint. The 
spectra was corrected for dilution and it was found that after each addition, the spectrum was 
different from the previous run (see Figure 2.10) indicating that some interaction does take place yet 
not to completion.     




Figure 2.10: Overlapped UV-Vis spectra of C2 (1mM) after each addition of DMSO from 0-100 
equivalents. 
Another study was conducted where C2 was combined with 100 equivalents of DMSO and UV-Vis 
spectra were recorded over a period of 18 hours. The reaction still did not reach completion according 
to the absorbance recorded. The conditions could not be modified any further due to time constraints. 
Further investigations will be done in future.  
 
2.2.4. Cyclic voltammetry 
Electrochemistry is an important factor to consider in drug development since it predicts what active 
species is formed and how it behaves once it has been administered. It can also be used to probe how 
a drug will be metabolized, how it will interact with DNA, what binding interactions will occur between 
compounds and proteins in vitro, etc.23 An electrochemical technique, i.e. cyclic voltammetry, was 
used to study the electron transfer processes of a solution of complexes C1-C6 in acetonitrile using 
0.2 M TBAPF6 as the supporting electrolyte across a wide range of potential energy (-2500 – 2500 mV) 
that covers the cell potential range of -40 – 70 mV. The working electrode used was the glassy carbon, 
whereas the reference electrode was an Ag/AgNO3 electrode and platinum wire as the counter 
electrode.  The scans were conducted on a full scale of 100 𝜇A at a scan rate of 100 mV/s. 
 
Table 2.8: Potential (mV) of oxidation and reductions obtained for Dpa and the chlorido complexes 
C1, C2 and C3 (↔ = reversible electron transfer reaction). 
 Potential range 
(mV) 








s -1000-1499  -1121 -1485 -1222 
 
    
-1500-1999 -1862 -1830   -1724↔ -1364 
 
 
-2000-2500  -2356 
-2008 




















260 310 360 410 460 510
0 Equiv. 1 Equiv. 5 Equiv. 10  Equiv. 15  Equiv.
20  Equiv. 25  Equiv. 50  Equiv. 100  Equiv.
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Table 2.9: Potential (mV) of oxidation and reductions obtained for iodido complexes C4, C5 and C6 (↔ 
= reversible reductions). 
 Potential 
range (mV) 








s -1000-1499 -1452 -1020 -1488 
-1500-1999 -1855 -1428 ↔ -1238 -1736 








 1056 1063 1032 
 
 
Figure 2.11: Voltammogram (reduction-oxidation) of Dpa ligand at a scan rate of 100 mV/s. 
From the voltammogram of the Dpa ligand (see Figure 2.11 above), we can deduce that the ligand 
induces redox activity however it does not undergo any reduction or oxidation. A redox active ligand 
then binds a metal centre that readily undergoes change in oxidation state to make the complexes, 
this results in a change of the redox activity of the ligand. This is seen on the voltammogram of 
complexes C1-C6. The potentials at between -70 and -640 mV are due to PF6- and are not involved in 
the redox potential of the complexes. The voltammogram of Ir complexes C1 and C4 both show 
irreversible oxidations at two potentials, Epa = 1318 mV for C1 and at Epa = 1056 mV for C4. These 
oxidations may be attributed to Ir(III) → Ir(IV). Ru complexes C3 and C6 also undergo an oxidation 
process at Epa = 1266 mV and Epa = 1032 mV respectively, an oxidation associated with the Ru(II) → 
Ru(III). An oxidation of the metals of complexes C2 and C5 to a higher oxidation state, Rh(III) → Rh(IV), 
is also observed at anodic potentials of 1119 mV and 1063 mV respectively. The oxidation observed 
for complexes C1-C6 are not reversible, this suggests that once the metals undergo the electron 
transfer process, the oxidated species is not stable and rapidly undergoes another reaction. From the 
results obtained, it is evident that the oxidation of the iodido complexes is a relatively facile process 
in comparison to the chlorido complexes since they oxidise at lower potentials. This is related to the 
donating ability of the halogen ligand. Iodine is less electronegative than chlorine i.e., it is a better 
electron donor, this means that loss of electrons of this complex will occur easier than for the chlorido 
complexes. The voltammograms of complexes C1-C6 (see Figure 2.12 below), show reduction and 
quasi-reversible processes (indicated by ↔ on Table 2.8 and 2.9) which can be attributed to the 
-2500-1500-5005001500
Dpa
Potential, mV vs SCE 
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halogenido ligands being cleaved off. A study of the electrochemistry of complexes C7-C12 was not 





Figure 2.12: Cyclic voltammogram (reduction-oxidation) of C1-C6 ligand at a scan rate of 100 mV/s. 
Using HPLC, the purity analysis of the complexes was done and good (95-99%) HPLC traces were 
obtained. All complexes but C2 was analysed using trifluoroacetic acid (TFA) in methanol as an ion 
pairing agent. Complexes C2 and C8 did not generate good traces using TFA, this may be due to TFA 
decomposing the complex or driving the complexes to hydrolyse. HPLC of complex C2 was then done 
in H2O/ MeCN using a high concentration of sodium chloride (NaCl) to supress any hydrolysis. HPLC of 
C8 could not be obtained due to time constraints, the same HPLC method will be used to analyse it. A 














Potential, mV vs SCE 
Potential, mV vs SCE 
Potential, mV vs SCE 




Figure 2.14: HPLC chromatogram of complex C10 with 98% purity. 
 
2.3. Summary 
Twelve complexes (C1-C12) of the ligand 2,2’-dipyridylamine (Dpa), of which six were new, were 
synthesized successfully in moderate to good yields. They were characterized using FTIR, 1H NMR, 13C 
NMR (C7-C12), ESI-mass spectrometry (C7-C12), XRD (C2, C5, C7 and C9), HPLC and CV (C1-C6). To 
obtain the purity of the complexes, HPLC studies were conducted in methanol. It was found that 
complexes were 95-99 % pure. XRD proved beyond reasonable doubt that the metal coordinates to 
Dpa via the nitrogen atoms of the pyridyl rings.  DMSO interaction studies using NMR suggested that 
all complexes may be stable in DMSO even after 24 hours of standing at room temperature, however, 
UV-Vis studies suggest otherwise. More studies are required in order to confirm the reactivity of 
complexes C1-C12 with DMSO. Cyclic voltammetry showed that complexes C1-C6 undergo irreversible 
oxidation reactions due to the unstable nature of the oxidated species that may be involved in other 
reactions immediately after the electron transfer preventing it from reversing the oxidation.  
 
2.4. Experimental Section 
2.4.1. Materials and Instrumentation 
Chemicals and reagents. Metal dimer starting material IrCl3.3H20, RhCl3.H2O and RuCl3.3H2O were all 
purchased from Heraeus Metals. 2,2’-dipyridylamine (95 %), 1,2,3,4,5-cyclopentadiene, ammonium 
hexafluorophosphate, ammonium nitrate, trifluoroacetic acid (TFA), sodium chloride, Tetra-n-butyl 
ammonium perchlorate (TBAClO4) and all reagent solvents (analytical grade) were obtained from 
Sigma Aldrich (Merck). Methanol used for reactions was distilled before use, all other solvents and 
reagents were used as received.   Deuterated solvents methanol-d4 and dimethylsulfoxide-d6 were 
obtained from Cambridge. HPLC solvents, i.e., H2O, MeOH and MeCN, were also used as received. 
 
Instrumentation. IR spectroscopy was performed using a NICOLET FTIR with an ATR accessory. 1H and 
13C NMR was recorded on a 400 MHz Varian Unity Inova spectrometer. Mass spectrometry was 
performed using a Waters Synapt G2 instrument in the positive ionisation mode.  
HPLC was conducted on an Agilent 1200 system with a quad pump and DAD detector using a Kinetex 
C180 100 Å, 150 x 4.6 mm diameter with 5𝜇M pore sizes. For C1, C3, C4-C7, C9-C11, H₂O 0.1 % TFA / 
MeOH 0.1 % TFA was used at gradients of t = 0 min 10 % A, t = 20 min 90 % A, t = 30 min 90 % A, t = 
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31 min 10 % A and t = 45 min 10 % A over a 45 min period. Flow rate was 1 mL min¯¹, and the detection 
wavelength was set at 254 nm, 260 nm and 300 nm with the reference wavelength at 360 nm. Sample 
injections were half the loop volume (50 μL) with needle washes of 50 % H₂O/MeOH between 
injections. It was assumed that all species have the same extinction coefficient at 254 nm, 260 nm and 
300 nm. All peaks were manually integrated to gain the percentage area. Samples were dissolved in 
10 % MeOH / 90 % H₂O at ca. 100 μM. The mobile phase for C2 was 50mM NaCl in H₂O/ MeCN 3:1 
50mMNaCl at gradients t = 0 min 10 % B, t = 10 min 20 % B, t = 20 min 60 % B, t = 25 min 100 % B, t = 
30 min 100 % B, t = 35 min 10% B and t = 40 min 10% over a 40 min period. Flow rate was 1 mL min¯¹, 
and the detection wavelength was set at 254 nm, 290 nm, 300 nm and 320 nm with the reference 
wavelength at 360 nm. Sample injections were half the loop volume (50 μL) with needle washes of 50 
% H₂O/MeCN between injections. It was assumed that all species have the same extinction coefficient 
at 254 nm, 290 nm, 300 nm and 320 nm. All peaks were manually integrated to gain the percentage 
area. Samples were dissolved in 10 % MeCN / 90 % H₂O at ca. 100 μM.  
UV-Vis was analysed using a Macro Cell 110-QS cuvette with a 10mm light path and SPECTROstar Nano 
Microplate reader.  
Electrochemical measurements were recorded using Basi Epsilon Eclipse Electrochemical 
Analyzer Potentiostat/Galvanostat. A three-electrode system consisting of a glassy carbon disk as the 
working electrode, a platinum wire as the counter/auxiliary electrode and Ag/AgNO3 as the reference 
electrode. The electrodes were mounted in a single-compartment cell configuration. Cyclic 
voltammograms were obtained from a 10-3 M stock solution of analyte in acetonitrile containing 0.1 M 
of the supporting electrolyte, i.e., TBAP (tetra-n-butylammonium fluoride).  
2.4.2. General Method for synthesis of C1-C6 
2,2’-dipyridylamine (1 equiv.) was dissolved in dry methanol (4 mL) and the appropriate metal dimer 
(0.5 equiv.) was added. The mixture was reacted in a microwave for 1 minute at 100°C. Solution was 
cooled to room temperature and NH4PF6 (1 equiv.) was added. The reaction was stirred at room 
temperature. The reaction was monitored with TLC to see the consumption of starting material. When 
starting material could no longer be detected, reaction mixture was stirred for a further 2 hours. Crude 
precipitate at the end of the reaction was filtered off, redissolved in acetone and filtered through 
celite. The volume of the filtrate was reduced and recrystallised through the addition of diethyl ether 
and the complexes precipitated out as crystalline powders. Complexes were isolated in moderate to 
good yields (70-78 %) as yellow, orange and red crystalline powders. 
 
2.4.2.1. [Ir(η5-Cp*)(dpa)Cl]PF6 (C1) 
 
The dimer [Ir(µ-Cl)(η5-(Cp*))Cl2] (50 mg, 0.063 mmol) was reacted with Dpa (23 mg, 0.134 mmol) for 
3 hours and NH4PF6 (24 mg, 0.147 mmol) was then added. The product (C1) was isolated as a yellow 
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crystalline solid (61 mg, 72% yield).IR (ATRcm-1): 667, 749, 782, 832, 876, 1028, 1162, 1226, 1351, 
1386, 1435,1472, 1490, 1522, 1582, 1628, 3022, 3083, 3130, 3183. 1H NMR (400 MHz, methanol-d4) 
δ 8.43 (d, J(H4 and H12) 5.8 Hz , 2H, H2 and H10), 7.95 (t, J(H3, H5, H11 and H13) = 8 Hz, 2H, H4 and H12), 
7.30 (d, J(H4 and H12) = 8.2 Hz, 2H, H5 and H13), 7.25 (t, J (H2, H4, H10 and H12)= 6.1 Hz, 2H, H3 and H11), 
1.47 (s, 15H, H19 – H23). HPLC: retention time of 11.25 min = 98% pure. 
 
2.4.2.2. [Rh(η5-Cp*)(dpa)Cl]PF6 C2:  
 
The dimer [Rh(µ-Cl)(η5-(Cp*))Cl2] (50 mg, 0.081 mmol) was reacted with Dpa (27 mg, 0.157 mmol) for 
3 hours and NH4PF6 (28 mg, 0.171 mmol) was then added. The product (C2) was isolated as a yellow 
crystalline solid (68 mg, 72% yield). IR (ATR, cm-1): 681, 739, 772, 834, 904, 1021, 1078, 1126, 1161, 
1233, 1352, 1376, 1470, 1518, 1584, 1624, 2922, 3384. 1H NMR (400 MHz, methanol-d4) δ 8.44 (d, 
J(H4 and H12) 4.8 Hz , 2H, H2 and H10), 7.98 (t, J(H3, H5, H11 and H13) = 7.8 Hz, 2H, H4 and H12), 7.28-7.32 
(m, 4H, H3, H5 , H11 and H13), 1.49 (s, 15H, H19-23). HPLC: retention time of 18.889 min = 99% pure. 
 
2.4.2.3. [Ru(η5-(p-cymene))(dpa)Cl]PF6 C3: 
 
 
The dimer [Ru(µ-Cl)( η5-(p-cymene))Cl2]2 (50 mg, 0.082 mmol) was reacted with Dpa (29 mg, 0.169 
mmol) for 2 hours and NH4PF6 (29 mg, 0.178 mmol) was then added. The product (C3) was isolated as 
an orange powder (0.035 mg, 74% yield). IR (ATR, cm-1): 677, 763, 829, 878, 965, 1024, 1058, 1091, 
1160, 1233, 1279, 1341, 1436, 1464, 1489, 1522, 1582, 1625, 2362, 3084, 3160, 3230.1H NMR (400 
MHz, methanol-d4) δ 8.63 (d, J(H4 and H12) 5.8 Hz , 2H, H2 and H10), 7.92 (t, J(H3, H5, H11 and H13) = 7.8 
Hz, 2H, H4 and H12), 7.16-7.24 (m, 4H, H3, H5 , H11 and H13), 5.66 (d, J (H25 and H26)= 6 Hz, 2H, H24 and 
H27), 5.56 (d, J (H24 and H27)= 6 Hz, 2H, H25 and H26), 2.65 (s, 1H, H31), 2.09 (s, 3H, H29), 1.22 (d, J (H31)= 
7.2 Hz, 6H, H32 and H33). HPLC: retention time of 10.188 min = 95% pure. 
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2.4.2.4. [Ir(η5-Cp*)(dpa)I]PF6: C4: 
 
 
The dimer [Ir(µ-I)(η5-(Cp*))I2]2 (50 mg, 0.043 mmol) was reacted with Dpa (15 mg, 0.093 mmol) for 3 
hours and NH4PF6 (13 mg, 0.080 mmol) was then added. The product (C4) was isolated as a yellow 
crystalline powder (52 mg, 78% yield).IR (ATR, cm-1): 683, 740, 768, 831, 875, 906, 1025, 1079, 1125, 
1161, 1231, 1359, 1384, 1431, 1471, 1520, 1583, 1626, 1702, 2359, 2912, 3363. 1H NMR (400 MHz, 
methanol-d4) δ 8.65 (d, J(H4 and H12) 6 Hz , 2H, H2 and H10), 7.98 (t, J(H3, H5, H11 and H13) = 7.2 Hz, 2H, 
H4 and H12), 7.28 (d, J(H4 and H12) = 8 Hz, 2H, H5 and H13), 7.25 (t, J (H2, H4, H10 and H12)= 65.8 Hz, 2H, 
H3 and H11), 1.62 (s, 15H). HPLC: retention time of 13.925 min = 95% pure. 
 
2.4.2.5. [Rh(η5-Cp*)(dpa)I]PF6 C5: 
 
The dimer [Rh(η5-Cp*)(dpa)I]PF6 (50 mg, 0.051 mmol) was reacted with Dpa (17 mg, 0.099 mmol) for 
3 hours and NH4PF6 (18 mg, 0.114 mmol) was then added. The product (C5) was isolated as orange 
shiny crystalline powder (49 mg, 71% yield).IR (ATRcm-1): 680, 739, 768, 827, 870, 1020, 1079, 1123, 
1159, 1124, 1213, 1266, 1356, 1378, 1469, 1489, 1519, 1583, 1624, 1696, 2980, 3377. 1H NMR (400 
MHz, methanol-d4) δ 8.67 (d, J(H4 and H12) 1.6 Hz , 2H, H2 and H10), 7.98 (t, J(H3, H5, H11 and H13) = 7.8 
Hz, 2H, H4 and H12), 7.28  (d, J(H4 and H12) = 8.4 Hz, 2H, H5 and H13), 7.25 (t, J (H2, H4, H10 and H12)= 6.6 
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The dimer [Ru(µ-I)( η5-(p-cymene))I2]2 (50 mg, 0.051 mmol) was reacted with Dpa (17 mg, 0.099 mmol) 
for 2 hours and NH4PF6 (19mg, 0.117 mmol) was then added. The product (C6) was isolated as a red 
shiny crystalline powder (0.045 mg, 70% yield). IR (ATR, cm-1): 671, 747, 766, 832, 881, 1033, 1058, 
1087, 1119, 1159, 1169, 1232, 1347, 1381, 1433, 1466, 1523, 1583, 1625, 1916, 2966, 3321, 3368, 
3852.1H NMR (400 MHz, methanol-d4) δ 8.81 (d, J(H4 and H12) 6 Hz , 2H, H2 and H10), 7.89 (t, J(H3, H5, 
H11 and H13) = 7.9 Hz, 2H, H4 and H12), 7.16 (d, 2H, J (H4 and H12) = H5  and H13, 2H, H5 and H13), 7.12 (t, 
J (H2, H4, H10 and H12) 7.9 Hz , 2H, H3 and H11), 5.66 (d, J (H25 and H26)= 6.4 Hz, 2H, H24 and H27), 5.56 (d, 
J (H24 and H27)= 6.4 Hz, 2H, H25 and H26), 2.65 (s, 1H, H31), 2.09 (s, 3H, H29), 1.22 (d, J (H31)= 6.8 Hz, 6H, 
H32 and H33). HPLC: retention time of 13.312 min = 97% pure. 
 
2.4.3. General Method for synthesis of C7-C12 
2,2’-dipyridylamine (1 equiv.) was dissolved in dry methanol (4 mL) and the appropriate metal dimer 
(0.5 equiv.) was added. The mixture was reacted in a microwave for 1 minute at 100°C. Solution was 
cooled to room temperature and NH4NO3 (1 equiv.) was added. The reaction was stirred at room 
temperature. The reaction was stirred overnight for a further ~18 hours. The volume of filtrate was 
reduced and recrystallised through the addition of diethyl ether and the complexes precipitated out 
as crystalline powders.  Complexes were isolated in moderate to good yields (41-86 %) as yellow and 
orange and crystalline powders. 
 
2.4.3.1. [Ir(η5-Cp*)(dpa)Cl]NO3 C7: 
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The dimer [Ir(µ-Cl)(η5-(Cp*))Cl2] (107 mg, 0.134 mmol) was reacted with Dpa (46 mg, 0.269 mmol) for 
18 hours and NH4NO3 (23 mg, 0.287 mmol) was then added. The product (C7) was isolated as a yellow 
a powder (134 mg, 86% yield).IR (ATRcm-1): 669, 700, 770, 780, 827, 843, 873, 906, 1035, 1073, 1109, 
1124, 1157, 1213, 1234, 1262, 1310, 1362, 1391, 1440, 1470, 1487, 1528, 1580, 1614, 1637, 2918, 
3065, 3179. 1H NMR (400 MHz, methanol-d4) δ 8.42 (d, J(H4 and H12) 6 Hz , 2H, H2 and H10), 7.95 (t, 
J(H3, H5, H11 and H13) = 7.8 Hz, 2H, H4 and H12), 7.32 (d, J(H4 and H12) = 8.2 Hz, 2H, H5 and H13), 7.24 (t, J 
(H2, H4, H10 and H12)= 6.7 Hz, 2H, H3 and H11), 1.47 (s, 15H, H19 – H23). 13C NMR (400 MHz, methanol-d4) 
δ 153.62 (C6,8), 153.37 (C2,10), 142.38 (C4,12), 122.20 (C3,11), 115.35 (C5,13), 89.55 (C14-18), (49.00 methanol 
CH3)8.57 (C19-23). ESI+ MS (m/z) 534.1289 [M]+. HPLC: retention time of 11.25 min = 98% pure 
 
2.4.3.2. [Rh(η5-Cp*)(dpa)Cl]NO3 C8: 
 
  
The dimer [Rh(µ-Cl)(η5-(Cp*))Cl2] (100 mg, 0.162 mmol) was reacted with Dpa (50 mg, 0.292 mmol) 
for 18 hours and NH4NO3 (26 mg, 0.325 mmol) was then added. The product (C8) was isolated as a 
yellow powder (0.138 mg, 84% yield). IR (ATR, cm-1): 667, 699, 741, 771, 827, 842, 873, 904, 1019, 
1036, 1084, 1122, 1156, 1234, 1262, 1311, 1356, 1389, 1437, 1467, 1527, 1579, 1634, 2955. 1H NMR 
(400 MHz, methanol-d4) δ 8.45 (d, J(H4 and H12) 6.8 Hz , 2H, H2 and H10), 8.09 (t, J(H3, H5, H11 and H13) 
= 7.9 Hz, 2H, H4 and H12), 7.30-7.34 (m, 4H, H3, H5 , H11 and H13), 1.50 (s, 15H, H19-23). HPLC: retention 
time of 18.889 min = 99% pure. 13C NMR (400 MHz, methanol-d4) δ 153.81 (C6,8), 152.71 (C2,10), 142.21 
(C4,12), 122.06 (C3,11), 115.65 (C5,13), 97.95 (C14-18), (49.00 methanol CH3) 9.85 (C19-23). ESI+ MS (m/z) 
444.0718 [M]+. 
 
2.4.3.3. [Ru(η5-(p-cymene))(dpa)Cl]NO3 C9: 
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The dimer [Ru(µ-Cl)( η5-(p-cymene))Cl2]2 (100 mg, 0.163 mmol) was reacted with Dpa (56 mg, 0.327 
mmol) for 18 hours and NH4NO3 (26 mg, 0.325 mmol) was then added. The product (C9) was isolated 
as an orange powder (68 mg, 41% yield). IR (ATR, cm-1): 662, 766, 826, 869, 886, 922, 996, 1024, 1062, 
1088, 1120, 1158, 1223, 1315, 1354, 1382, 1431, 1469, 1528, 1582, 1613, 1634, 2965.1H NMR (400 
MHz, methanol-d4) δ 8.63 (d, J(H4 and H12) 6.2 Hz , 2H, H2 and H10), 7.92 (t, J(H3, H5, H11 and H13) = 5.8 
Hz, 2H, H4 and H12), 7.19-7.22 (m, 4H, H3, H5 , H11 and H13), 5.67 (d, J (H25 and H26)= 6.4 Hz, 2H, H24 and 
H27), 5.57 (d, J (H24 and H27)= 6.4 Hz, 2H, H25 and H26), 2.62 (s, 1H, H31), 2.10 (s, 3H, H29), 1.23 (d, J (H31)= 
4 Hz, 6H, H32 and H33). 13C NMR (400 MHz, methanol-d4) δ 155.72 (C6,8), 15.45 (C2,10), 141.77 (C4,12), 
120.66 (C3,11), 115.02 (C5,13), 108.13 (C30) 101.34 (C28), 86.83 (C24,27), 85.21 (C25,26), (49.00 methanol CH3) 
32.18 (C31), 22.34 (C32,33), 18.36 (C29). ESI+ MS (m/z) 442.0929 [M]+, HPLC: retention time of 10.257 min 
= 94% pure. 
 





The dimer [Ir(µ-I)(η5-(Cp*))I2]2 (44 mg, 0.038 mmol) was reacted with Dpa (13 mg, 0.076 mmol) for 18 
hours and NH4NO3 (7 mg, 0.087 mmol) was then added. The product (C10) was isolated as a yellow 
crystalline powder (35 mg, 67% yield).IR (ATR, cm-1): 672, 702, 739, 766, 840, 876, 906, 950, 1022, 
1079, 1122, 1154, 1231, 1244, 1300, 1363, 1383, 1398, 1429, 1470, 1488, 1523, 1579, 1625, 1645, 
2909, 2954. 1H NMR (400 MHz, methanol-d4) δ 8.66 (d, J(H4 and H12) 6.8 Hz , 2H, H2 and H10), 7.93 (t, 
J(H3, H5, H11 and H13) = 7.90 Hz, 2H, H4 and H12), 7.16 (d, J(H4 and H12) = 8.2 Hz, 2H, H5 and H13), 7.16 (t, 
J (H2, H4, H10 and H12)= 9.2 Hz, 2H, H3 and H11), 1.55 (s, 15H, H19-H23). ESI+ MS (m/z) 626.0641 [M]+, 
HPLC: retention time of 14.329 min = 98% pure. 
 
2.4.3.5. [Rh(η5-Cp*)(dpa)I]NO3 C11: 
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The dimer [Rh(µ-I)( η5-Cp*)I2]2 (100 mg, 0.102 mmol) was reacted with Dpa (34 mg, 0.0.199 mmol) 
for 18 hours and NH4NO3 (17 mg, 0.212 mmol) was then added. The product (C11) was isolated as an 
orange shiny crystalline powder (94 mg, 78% yield). IR (ATR cm-1): 707, 740, 768, 839, 877, 905, 965, 
1018, 1036, 1076, 1120, 1153, 1231, 1261, 1301, 1360, 1382, 1427, 1468, 1487, 1523, 1578, 1623, 
2956, 3054, 3154.1H NMR (400 MHz, methanol-d4) δ 8.66 (d, J(H4 and H12) 6 Hz , 2H, H2 and H10), 7.98 
(t, J(H3, H5, H11 and H13) = 7.9 Hz, 2H, H4 and H12), 7.31  (d, J(H4 and H12) = 8.4 Hz, 2H, H5 and H13), 7.25 
(t, J (H2, H4, H10 and H12)= 6.5 Hz, 2H, H3 and H11), 1.63 (s, 15H, H19 – H23). 13C NMR (400 MHz, methanol-
d4) δ 156.02 (C6,8), 153.80 (C2,10), 142.11 (C4,12), 121.80 (C3,11), 115.33 (C5,13), 98.50 (C14-18), (49.00 
methanol CH3) 9.85 (C19-23). ESI+ MS (m/z) 538.0073 [M]+, HPLC: retention time of 13.413 min = 97% 
pure. 
 




The dimer [Ru(µ-I)( η5-(p-cymene))I2]2 (100 mg, 0.102 mmol) was reacted with Dpa (35 mg, 0.204 
mmol) for 18 hours and NH4PF6 (19 mg, 0.249 mmol) was then added. The product (C12) was isolated 
as a red shiny crystalline powder (85 mg, 70% yield). IR (ATR, cm-1): 670, 746, 764, 802, 826, 558, 1024, 
1056, 1085, 117, 1155, 1233, 1317, 1345, 1376, 1432, 1466, 1489, 1520, 1580 ,1623, 2966, 2966, 3051, 
3150. 1H NMR (400 MHz, methanol-d4) δ 8.81 (d, J(H4 and H12) 4.2 Hz , 2H, H2 and H10), 7.89 (t, J(H3, 
H5, H11 and H13) = 6.8 Hz, 2H, H4 and H12), 7.19 (d, 2H, J (H4 and H12) = 6 H5  and H13, 2H, H5 and H13), 
7.12 (t, J (H2, H4, H10 and H12) 6.6 Hz , 2H, H3 and H11), 5.68 (d, J (H25 and H26)= 6.4 Hz, 2H, H24 and H27), 
5.62 (d, J (H24 and H27)= 6.4 Hz, 2H, H25 and H26), 2.66 (s, 1H, H31), 2.22 (s, 3H, H29), 1.22 (d, J (H31)= 3.2 
Hz, 6H, H32 and H33). 13C NMR (400 MHz, methanol-d4) δ 158.81.72 (C6,8), 154.36 (C2,10), 141.58 (C4,12), 
120.32 (C3,11), 114.69 (C5,13), 109.77 (C30) 100.81 (C28), 87.50 (C24,27), 84.52 (C25,26), (49.00 methanol CH3) 
32.63 (C31), 22.43 (C32,33), 19.59 (C29).  ESI+ MS (m/z) 533.9994 [M]+. 
 
 
2.4.4. Single crystal X-ray diffraction: 
 
Single crystals of C1 and C2 were grown from a solution of acetone and diethyl ether and single crystals 
of complexes C7 and C9 were grown from a solution of methanol and diethyl ether. Single-crystal X-
ray intensity data were collected on a Bruker 3-circle Apex II DUO X-ray diffractometer equipped with 
an INCOATEC IμS HB microfocus sealed tube (MoKα radiation λ = 0.71073 Å) fitted with a multilayer 
monochromator. Data were captured with a CCD (charge-coupled device) area detector. Data 
collection was carried out at 100 K using an Oxford Cryosystems cryostat (700 series Cryostream Plus) 
attached to the diffractometer. Data collection and reduction were carried out using the Bruker 
software package APEX3, using standard procedures. All structures were solved and refined using 
SHELX-2016 employed within the X-Seed3, environment. Hydrogen atoms were placed in calculated 
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positions using standard riding models. X-ray diffraction data are summarised in Table 2.10 and 2.11. 
Distances and angles were calculated using Mercury software version 4.3.1. 
 
Table 2.10.: Crystal data and structure refinement details of complexes C1 and C7. 
 
 C1 C7 
Empirical formula C20H24ClF6IrN3P C20H25ClN4O4Ru 
Formula weight 679.04 596.08 
Temperature (K) 100(2) 100(2) 
Wavelength (Å) 0.71073 0.71073 
Crystal system Orthorhombic monoclinic 
Space group P212121 P21/c 
 
Unit cell dimensions 
(Å, °) 
a 9.0227(7) a8.4482(14)  
b 15.3290(12) 16.812(3) 
c 16.4996(13) 14.096(2) 
𝜶 90 90 
𝜷 90 100.321(2) 
𝜸 90 90 
Volume (Å) 2282.0(3) 2071.3(6) 
Z 4 4 
Calculated density (g. cm-3) 1.976 1,911 
Absorption coefficient (mm-1) 6.100 6,604 
F000 1312 1160 
Crystal size (mm3) 0.200 ´ 0.069 ´ 0.047 0.204 ´ 0.121 ´ 0.056 
q range for data collection (°) 1.813 to 28.372 1.904 to 29.664 
Miller index ranges -12 ≤ h ≤ 12, -20 ≤ k ≤ 20, -
21 ≤ l ≤ 22 
 -12 ≤ h ≤ 12, -23 ≤ k ≤ 23, -
19 ≤ l ≤ 19 
Reflections collected 32000 53743 
Independent reflections 5700 [Rint = 0.0387] 5856 [Rint = 0.0529] 
Completeness to qmax (%) 0.998 0.999 
Max. and min. transmission 0.118 and 1.000 0.680 and 1.000 
Refinement method Full- matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
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Data/ restraints/ parameters 5700/ 25/ 362 5856 / 0 / 271 
Goodness-of-fit on F2 1.105 1.039 
Final R indices [I>2s(I)] R1 = 00478, wR2 = 0.1119 R1 = 0.0179, wR2 = 0.0390 
R indices (all data) R1 = 00493, wR2 = 0.1129 R1 = 0.0223, wR2 = 0.0403 
Largest diff. peak and hole (eÅ-3) 3.225 and -0.414 0.622 and -0.535 
Absolute structure parameter 0.0064(4)  
 
Table 2.11.: Crystal data and structure refinement details of complexes C2 and C9. 
 C2 C9 
Empirical formula C20H24ClF6N3PRh C20H25ClN4O4Ru 
Formula weight 589.72 521.96 
Temperature (K) 100(2) 100(2) 
Wavelength (Å) 0.71073 0.71073 
Crystal system Orthorhombic triclinic 
Space group P212121 p-1  
 
Unit cell dimensions 
(Å, °) 
a 9.0227 (7) 8.4482(14)  
b 15.3290 (12) 16.812(3) 
c 16.4996 (13) 14.096(2) 
𝜶 90 96.622(2) 
𝜷 90 106.129(2) 
𝜸 90 93.986(2) 
Volume (Å) 2275.0(4) 1034.81(19) 
Z 4 2 
Calculated density (g. cm-3) 1.722 1.675 
Absorption coefficient (mm-1) 1.001 0.922 
F000 1184 532 
Crystal size (mm3) 0.246 ´ 0.228 ´ 0.158 0.157 ´ 0.145 ´ 0.140 
q range for data collection (°) 1.812 to 30.501 1.739 to 29.635 
Miller index ranges -12 ≤ h ≤ 12, -21 ≤ k ≤ 21, -
23 ≤ l ≤ 23 
-11 ≤ h ≤ 11, -14 ≤ k ≤ 14, -
17 ≤ l ≤ 17 
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Reflections collected 42571 59403 
Independent reflections 6935 [Rint = 0.0387] 5830 [Rint = 0.0329] 
Completeness to qmax (%) 0.999 0.998 
Max. and min. transmission 0.876 and 1.000 0.950 and 1.000 
Refinement method Full- matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Data/ restraints/ parameters 6935/ 138/ 362 5830 / 4 / 286 
Goodness-of-fit on F2 1.043 1.059 
Final R indices [I>2s(I)] R1 = 0.0174, wR2 = 00421 R1 = 0.0190, wR2 = 0.0487 
R indices (all data) R1 = 0.0179, wR2 = 0.0423 R1 = 0.0201, wR2 = 0.0493 
Largest diff. peak and hole (eÅ-3) 0.437 and -0.345 0.459 and -0.674 
Absolute structure parameter 0.010(7)  
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Biological screening of organometallic complexes  
Chapter 1  
Chapter 
3.1.  Introduction 
As mentioned in Chapter 1, the study of metal complexes as new and effective medicines is advancing. 
With a global increase of reduced efficacy due to growing resistance, the necessity for viable new 
antiplasmodial drugs is evident. To combat this, researchers proposed incorporating metals into 
current drugs with the aim of improving their efficacy as well as overcoming resistance. This research 
led to the successful synthesis of the most advanced organometallic antimalarial drug today, i.e., 
ferrocene derivative of chloroquine, ferroquine. Drug discovery has now advanced past this stage of 
incorporating metals only into current drugs since it has been reported that incorporating metals into 
organic pharamacophores can improve their therapeutic efficacy.1,2 Complexes C1-C6 have previously 
been synthesized and evaluated against human ovarian cancer cell line, A2780, by Ŝtarha and co- 
workers. It was found that complexes C1, C4 and C5 were active.3,4 The applicability of known 
complexes C1-C6 as antiplasmodials has not been reported. The study of similar N, N’ organometallic 
complexes of the ligand picolinamide, reported by Almodares et al., evaluated for antitumor activity 
reports varying IC50 values with one ruthenium complex showing better potency than cisplatin on 
tested cells HT-29 (human colon cancer cell line) and MCF-7 (breast cancer cell line).5  
To make the complexes C7-C12, the halogenido counterions are exchanged for NO3-. Salt formation is 
an important property in drug discovery. One of the most important factors to consider when 
addressing the aqueous solubility of a compound is to consider salt formation. The formation of salts 
do not only influence a compound’s solubility, it may also affect its physicochemical, and biological 
properties such as toxicity and gastrointestinal absorption.6 The PF6- counterion is widely used in the 
synthesis of half-sandwich organometallic complex for antiplasmodial application. NO3- on the other 
hand, a biologically friendly species that is found in the body, is not used extensively. A study of the 
complexes with different counterions is done to investigate whether hexafluorophosphate or nitrate 
complexes would have better activity.  
Drug discovery is highly guided by pharmacology since the study of a potential drug candidates’ 
pharmacodynamic and pharmacokinetic properties is very important.7 During drug development, the 
physicochemical profiling of a drug with poor properties has proven to be a very costly mistake. The 
use of efficient and reliable high throughput in vitro assays to determine important properties of a 
drug have become crucial in the early stages of drug discovery.8 It is thus important that these 
properties need to be optimized before a drug could be classified as a drug candidate.9 Thorough 
investigations are required to gain a complete understanding of a drug’s therapeutic efficacy as well 
as its physicochemical properties to determine the drug’s fate. Amongst others, these properties 
influence how a drug will be delivered to its target site (method of delivery), as well as formulation.8  
In this chapter, the turbidimetric solubility, aquation studies and in vitro biological activity of the ligand 
(Dpa) and complexes (C1-C12) (Figure 3.1) will be discussed.    




Figure 3.1.: Structure of complexes C1-C12. 
Due to COVID-19 delays, the evaluation of complexes C7-C12 against two chloroquine sensitive P. 
falciparum strains of 3D7 and NF45 wa not done.  
 
3.2.   Results and Discussion 
3.2.1. Turbidimetric assay  
The solubility of a compound in aqueous based medium is one of the most important physicochemical 
properties to consider during drug discovery and development amongst others.10’11  The dose of 
administered drug that is able to enter the systemic circulation and still have therapeutic effect is 
influenced by the solubility.12-13 Low solubility in aqueous media can cause a drug candidate to be 
eliminated during the early stages of drug discovery, even before functional assessment as a potential 
drug candidate.10,14 Additionally, should the drug precipitate at concentration lower than the IC50 
value, the bioassays will be unreliable.12,14 Solubility of a compound is dependent on two factors which 
are the conditions of the solvent within which the compound is dissolved, and its structure pertaining 
to its physicochemical properties.12  
Drug developers usually employ medium to high throughput screening techniques to measure the 
solubility of potential candidates. The kinetic assay is a high throughput assay normally used for 
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determining in vitro solubility.15 The aqueous solubility of the Dpa ligand and the 12 complexes  (C1-
C12) were measured with hydrocortisone and reserpine as positive and negative control, respectively 
with the use of a kinetic assay.  
A detailed protocol is given in the experimental section (3.4.2). Briefly, a stock solution of each 
compound in DMSO was added to phosphate-buffered saline (PBS) which mimics physiological 
conditions and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer which is normally 
used in the in vitro P. falciparum assays in a 96-well plate. The plates were incubated at 25 °C, 
thereafter, the formation of any precipitate is determined by measuring the absorbance at 620 nm to 
produce the compound solubility range. A compound is considered to have poor solubility if it is lower 
than 10 µg/mL, if it ranges between 10-60 µg/mL then is has moderate solubility. Good solubility 
criterion is > 60 μg/mL. The solubility ranges of all compounds are summarized in Table 3.1 below.   
 
Table 3.1.: A summary of solubility ranges of Dpa ligand, its complexes (C1-C12) and the control 





µM µg/mL µM µg/mL 
Dpa 80-120 14-21 80-120 14-21 
Reserpine 20-40 12-24 40-80 24-49 
Hydrocortisone >160 >60 >160 >60 
C1 80-120 54-81 40-80 27-54 
C2 40-80 24-47 40-80 24-47 
C3 20-40 12-23 40-80 24-47 
C4 40-80 31-62 40-80 31-62 
C5 80-120 54-82 20-40 14-27 
C6 40-80 27-54 10-20 7-14 
C7 >160 95 >160 95 
C8 >160 81 >160 82 
C9  >160 81 >160 81 
C10 >160 110 80-120 55-83 
C11 >160 96 >160 96 
C12 >160 95 >160 95 
 
All the complexes demonstrated good aqueous solubility in DMSO up to a maximum concentration of 
200 µM. Dpa was moderately soluble up to 80 µM in both buffer solutions. As expected, reserpine 
showed moderate solubility whereas hydrocortisone was highly soluble even at maximum 
concentration in solution in both PBS and HEPES (see Figure 3.2 for demonstration in PBS).  
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Figure 3.2.: Absorbance curve of hydrocortisone and reserpine in DMSO (blue) and in PBS buffer 
(pink). 
Complexes with the PF6- counterion (C1-C6) presented varying solubility ranges. C1 showed moderate 
solubility in the HEPES buffer and showed slightly higher solubility in the PBS buffer. The same 
phenomenon is seen for rhodium iodido complex, C5. The solubility range in both buffer solutions was 
observed to be indistinguishable for complexes C4 and C2 at 40-80 µM. Although displaying varying 
poor to moderate solubilities, ruthenium complexes C3 and C6 showed the least aqueous solubility in 
comparison to the iridium (C1 and C4) and rhodium (C2 and C5) complexes. The reason why the 
ruthenium complexes were less soluble is not immediately clear, however, it could be due to the para-
cymene ligand. It could also be due to the strength of the interaction between the cation and the 
counterion, if the interaction is much stronger, it would be harder for the water molecule to solvate 
the ions causing it to go into solution. From these results, it shows that complexation improved the 
aqueous solubility of the ligand dpa except for complexes C3 and C6. On the contrary, complexes with 
the NO3- counterion (C7-C12) shows significantly improved solubility in comparison to the PF6- 
complexes. Complexes C7-C12 were soluble up to 200 µM with the exception of C10 presenting 
moderate to good solubility in the HEPES buffer. There is no significant pattern observed for chlorido 
vs iodido complexes which have the same metal for C1-C6. Complex C1, which has a chlorido ligand 
displays better solubility compared to its iodido counterpart (C4) in PBS buffer. The rhodium (C5) and 
ruthenium (C6) iodido complexes exhibit better solubility than their chlorido analogues in PBS buffer. 
However, the opposite is observed in the HEPES buffer.  
 
3.2.2.  Hydrolysis studies 
When a drug is administered a number of processes could occur that alters the structure of the 
compound. Metal complexes can undergo  ionization (oxidation/ reduction of the ligand or complex),  
ring opening of metal chelates  or a labile ligand such as a halide bound to the metal is displaced by a 
water molecule.16 These interactions can either activate or deactivate a drug. For metallodrugs, the 
metal centre is susceptible to interaction with other molecules present in biological media such as 
water.  Aqua complexes have been reported to be more reactive than their chlorido derivatives.17 
Additionally, this displacement of the chlorido atom by a water molecule serves as an activation step 
for some organometallic complexes aimed at the treatment of cancer.18 Reaction of metal complexes 
with water is especially important since it has been reported that the aqua species is likely the 
dominant species in in vitro biological assays.  The hydrolysis of  organoiridium C,N’ chelated 
complexes reported by Liu et al. was monitored by 1H NMR and it was found that all the complexes 
underwent rapid hydrolysis (less than ~ 5 minutes).19 This was important since the aqua adduct was 
found to be the active species. These complexes were then tested against A2780 human ovarian 
cancer cell line. Three of the complexes were found to show promising activity against the tested 
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strain, A2780.19 In this case, the ability of the complexes to undergo hydrolysis plays a role in the 
bioavailability of the active species. A small library of four N, N chelating half sandwich organometallic 
complexes were reported by Soldevila-Barreda et al.20 Stability of these complexes in aqueous 
medium was analysed with a hydrolysis study. Results obtained showed that hydrolysis of the metal-
ligand bond occurs instantaneously. In vitro screening of the complexes against A2780 cancer cell line 
illustrated that these complexes were moderately active.20 Thus, it is important to confirm whether 
complexes C1-C12 readily react with water.  
First, each complex was incubated in D2O in the presence of AgNO3 for 18 hours at 37°C (see Scheme 
3.1). AgNO3 is a known halide abstractor and was used to ensure that the aqua complex would be 
produced. 
 
Scheme 3.1: Synthesis of aqua species C1-D2O – C12-D2O. 
After 18 hours, each solution was filtered through celite, a drop or two of TMS (internal reference) 
was added and 1H NMR analysis was done on the filtrate. The proton spectra obtained was presumed 
to be that of the aqua species C1-D2O – C12-D2O where the chlorido or iodido ligand is displaced and 
a D2O molecule is subsequently bound to the metal. This zero-net charge of D2O results in the metal 
centre being doubly charged with PF6- and NO3- as counterions for complexes C1-C6 and two NO3- 
counterions for C7-C12. Secondly, each complex was then incubated in 75% D2O/ 25% MeOD-d4 (to 
solubilize less soluble complexes) at 37°C in the absence of AgNO3. Solutions were then filtered 
through celite before a drop of TMS was added and 1H NMR analysis was done on the filtrates. The 
spectra of the aqua species generated in the presence of AgNO3 was compared to that of each complex 
incubated without AgNO3 in order to examine whether the complexes readily undergo aquation.  
According the 1H spectra, iridium chlorido complex C1 (see Figure 3.3 below) does not undergo any 
aquation in a 75% D2O/25% MeOD-d4 solution after 18 hours of incubation. The generated aqua 
species, C1-H2O (red) does not overlap with the incubated species in the absence of AgNO3(blue). A 
shift of all pyridyl protons downfield for the incubated species without AgNO3 is observed, this signifies 
successful generation of the aqua adduct by incubation with AgNO3. The coordination of D2O to the 
metal centre changes the chemical environment of the pyridyl protons making them less shielded due 
to the increased positive nature of the metal centre. However, this indicates that complex C1 does not 
readily undergo hydrolysis in the absence of a halide abstractor. This is also observed for complexes 
C5, C6, C7, C10 as well as C11.  
 










Figure 3.3.: An overlap of the proton spectra (only pyridyl protons shown) of generated aqua 
species (red), i.e., complexes C1-D2O (no hydrolysis), C2-D2O (trace amounts of aqua species) and 
C9-D2O (~30% hydrolyse species), and that of incubated organometallic without AgNO3 (blue).  
 
Some aquation was observed for complexes C2, C3, C8 and C9. This was confirmed by the set of peaks 
that occur at similar shifts to the generated aqua species in the NMR spectra. For C2 and C8, only a 
small amount of the halogenido-complexes react with water.  For C3, based on the peak intensity, 
there is a higher ratio of the aqua species C3-D2O to chlorido complex at approximately 2.4: 1. Complex 
C9, on the other hand, displayed of the chlorido species in comparison to the aqua species with an 
approximated ratio of 1:1.5. Two sets of pyridyl protons attributed to two different species are 
observed for complex C12. The major species did not overlap with that of the aqua species suggesting 
that C12 does not undergo hydrolysis to completion. A summary of the result obtained for the 
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hydrolysis of complexes C1-C12 (Table 3.2) shows that the chlorido complexes undergo hydrolysis 
relatively faster than their iodido derivatives. A study of organoiridium complexes discussed above 
investigated the effect of exchanging a chloride ligand with pyridine on the rate of hydrolysis, in vitro 
activity as well as reactivity.17 The rapidly hydrolysable iridium chloride complex was evaluated  against 
a pyridine derivative and it was found that pyridine complex does not undergo hydrolysis. This was 
attributed to the pyridine blocking the site required by the water molecule to bind. It was concluded 
that the type of ligand sets binding to iridium will determine its reactivity. With an ionic radius of 0.181 
nm, chlorine is relatively smaller than iodine that has an ionic radius of 0.220 nm. This leads to an 
increase in the nephelauxetic effect, therefore, a greater electron cloud expansion of the metal onto 
the iodide ligand occurs. As a result, the bond between the metal and iodide ligand is more covalent, 
whereas that of the metal and chlorine is more ionic. In this way, iodine may be blocking aquation of 
the metals. 
 
Table 3.2.: Summary of Cl and I complexes that underwent aquation vs. those that did not. 
 NO aquation Aquation 
 Cl I Cl I 
 
PF6 
 C1 C2  
C5 C3 
C6  
NO3 C7 C10 C8 C12 
 C11 C9  
 
From the results shown above, all but one iodido complex, C12, did not undergo aquation. 
Additionally, C7, was the only chloride ligand bearing complex that did not generate an aqua species 
in the absence of AgNO3. Complexes C2, C3, C8, C9 and C12 appear to hydrolyse in the presence of 
deuterium oxide over a period of 18 hours. Since bioassays normally conduct drugs testing in aqueous 
medium, it is possible that the active species of these complexes is the aqua complex.  
 
3.2.3.  Antiplasmodial activity against P. falciparum  
The in vitro biological antimalarial activity of Dpa and complexes C1-C6 was evaluated against 3D7 CQ-
sensitive strain of P. falciparum parasite at Griffith University in the research group of Prof. Vicky 
Avery. Evaluation of the complexes C7-C12 was not done due to time constraints. 
The antimalarial activity of known antimalarials, i.e., artesunate, chloroquine and pyrimethamine, 
were also analysed (see figure 3.3) as reference standards. It was found that Dpa was not active, 
however, complexes C1-C6 showed some activity. The rhodium-chlorido complex C2 (IC50 = 4.72 𝜇M) 
showed the best activity relative to the other complexes whereas iridium-chlorido complex C1 (IC50 = 
8.93 𝜇M) showed the least activity.  




Figure 3.4.: Preliminary in vitro biological activity results of ligand Dpa, complexes C1-C6 and 
other known antimalarials against 3D7 P. falciparum strain. 
 
The iridium-iodido, derivative C4 (IC50 = 7.83 𝜇M), was more active than its chlorido derivative. This is 
also observed for the ruthenium complexes C3 (IC50 = 7.91 𝜇M) and C6 (IC50 = 7.57 𝜇M). For rhodium 
complexes C2 and C5, the chlorido derivative (C2) showed higher activity. This is postulated to be 
attributed to the complexes’ solubility in aqueous medium shown in table 3.1 since in vitro testing 
takes place in aqueous based medium. Romero-Canelón et al. conducted a study of the activity of 
iodido versus chlorido ruthenium and osmium complexes. The study showed that the iodido 
complexes exhibited better antiproliferative activity compared to the chlorido analogues.21 This 
difference in activity was attributed to charge distribution of the complexes. A comparison of the 
electrostatic potential surfaces of the chlorido and iodido complex highlights that the iodine ligand is 
more positively charged resulting in higher potency. The same can be proposed for the greater activity 
observed for the iodide complexes of iridium and ruthenium. In the parasite assay preparation, a 25 
mM solution of HEPES was used in the culture medium for the P. falciparum 3D7 strains. From the 
results of aqueous solubility of complexes in HEPES buffer, C4 (31-62 𝜇g/mL) is slightly more soluble 
than C1 (24-47 𝜇g/mL). This could mean that a higher concentration of C4 is still in solution than that 
of C1 after 72 hours of incubation which might result in more of C4 being transported into the parasite 
resulting in the complex having better activity.  This rationalization can be used for the rhodium 
complexes as well, C2 (24-47 𝜇g/mL) is slightly more soluble than C5 (14-27 𝜇g/mL) resulting in better 
activity to some extent. Furthermore, the lower solubility of C6 (7-14 𝜇g/mL) compared to that of C3 
(24-47 𝜇g/mL) is compromising to its activity. In comparison to known antimalarials (IC50 = 0.00548- 
0.0167 𝜇M), these complexes did not show good activity. Incorporation of the metals to the organic 
scaffold, Dpa, certainly improved its activity against 3D7 CQ-sensitive strains. The antiproliferative 
activity of the complexes showed that rhodium (C2 and C5) was the most active, followed by 







































in vitro activity of evaluate compounds
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We were also able to carry out antiplasmodial testing for Dpa ligand, complexes (C1-C6) and dimers 
([Ir(Cp*)Cl2]2, [Ir(Cp*)I2]2, [Rh(Cp*)Cl2]2, [Rh(Cp*)I2]2, [Ru(p-cymene)Cl2]2 and [Ru(p-cymene)I2]2) was 
done against the drug sensitive strain of P. falciparum, NF54, in the lab of Prof. Lubbe Wiesner at the 
University of Cape Town. The known antimalarials, CQ and artesunate were also screened as reference 
standards.   Both a two- and a three- day assay was conducted in order to observe whether the 
incubation period would alter the compounds efficacy. A summary of the mean (two tests) IC50 values 
and their standard deviations were summarized on table 3.3 below.  
Table 3.3.: Mean antiplasmodial activity of tested dimers, complexes (C1-C6) and known 
antimalarials CQ and artesunate against NF54, a drug sensitive strain of Plasmodium falciparum. 
Sample 










Dpa >5000 NA >5000 NA 
C1 >5000 NA >5000 NA 
C2 >5000 NA >5000 NA 
C3 >5000 NA >5000 NA 
C4 >5000 NA >5000 NA 
C5 >5000 NA >5000 NA 
C6 >5000 NA >5000 NA 
[Ir(Cp*)Cl2]2 4802.7 160.1 >5000 NA 
[Ir(Cp*)I2]2 >5000 NA >5000 NA 
[Rh(Cp*)Cl2]2 4955.7 25.1 >5000 NA 
[Rh(Cp*)I2]2 >5000 NA >5000 NA 
[Ru(p-cymene)Cl2]2 >5000 NA >5000 NA 
[Ru(p-cymene)I2]2    >5000 NA >5000 NA 
Chloroquine 8.1 3.3 4.9 0.0 
Artesunate 2.9 1.4 4.1 0.6 
 
Following two- and three-day incubation, none of the complexes showed any activity at a 
concentration range of 5.00 – 0.31 µg/ mL. Subsequent to the two-day incubation, dimers [Ir(Cp*)Cl2]2 
and [Rh(Cp*)Cl2]2 displayed weak antiplasmodial activity with IC50 values of 4802.7 ± 160.1 ng/mL and 
4955.7 ± 25.1 ng/mL respectively (see table 3.3). This activity was not observed after the three-day 
incubation. The reference standards, CQ and artesunate, displayed very good activity. Complexes 
displayed weak activities against the NF54 strain above. This may be due to the fact that the growth 
media was supplemented with hypoxanthine which could counter the compounds’ MOA resulting in 
a lag time, thus, activity may only appear after longer periods of incubation (over 3 days). This was 
also observed for known active antimalarial drugs pyrimethamine, sulfadiazine and sulfadoxine which 
were tested in the same assay, the complexes showed no activity. Additionally, complexes C1-C6 have 
a high molecular weight, thus their molar concentration at 5𝜇g/mL is much lower than an organic 
molecule with a lower molecular weight. For this reason, the complexes may show no activity.  
 
 




The solubility of complexes C1-C12 in aqueous media was carried out with the use of a high-
throughput kinetic assay. It was found that PF6- complexes (C1-C6) had different solubilities ranging 
from poor to good solubility whereas the NO3- complexes (C7-C12) had good solubility in both buffer 
solutions, generally better than the PF6- derivatives.  Aquation studies of the complexes revealed that 
all but one of the chlorido complexes (C7) and one iodido complexes (C12) underwent aquation.  The 
preliminary in vitro antiplasmodial activity of complexes C1-C6 against the 3D7 P. falciparum strain 
showed that complex activity may be relative to the complexes’ solubility in HEPES buffer. Evaluation 
of the complexes against NF54 P. falciparum strain of malaria showed to be inactive following a two- 
and three- day assay. Further testing up to a higher mass concentration of 20 ug/mL for complexes oh 
higher molecular weight may yield better IC50 values since their molar concentration would be higher 
at a higher mass concentration. Due to time constraints, the NO3- complexes were not screened for 
antiplasmodial activity. This will be pursued as part of our future work to determine if the difference 
in counter ion will influence bioactivity. 
 
3.4. Experimental Section 
3.4.1. Materials 
Chemicals and reagents: Phosphate Buffered Saline (0.01 M in 200 mL distilled water), N-(2-
Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (1.191 g, 5.0 mmol), reserpine, hydrocortisone, 
silver nitrate were obtained from Sigma Aldrich (Merck). Deuterium oxide-d2 solvent was purchased 
from Sigma. Deuterated methanol solvent was from purchased from Sigma.  
Instrumentation: 
1H NMR was recorded on a 400 MHz Varian Unity Inova spectrometer. 
3.4.2. Turbidimetric Assay  
A 0.01 M pH 7.4 Phosphate Buffered Saline (PBS) solution was prepared by dissolving one PBS tablet, 
in 200 mL distilled water at 25 °C in order to yield a buffered solution containing 0.01 M phosphate 
buffer, 0.003 M KCl and 0.14 M NaCl. The solution was allowed to equilibrate at 25 °C for one hour 
upon which the pH was confirmed with a pH meter. The solution was then filtered through a 0.45 μM 
Nylon syringe filter in order to remove any undissolved particulates. A N-(2-Hydroxyethyl)piperazine-
N′-(2-ethanesulfonic acid) (HEPES) buffer solution was prepared. This was done by dissolving 1.191 g 
of HEPES free acid in 180 ml of distilled H2O. A 0.1M solution of NaOH was added in 1mL equivalents 
until the pH was adjusted to 7. The solution was then made up to 200 mL with distilled H2O. A 10 mM 
stock solution in DMSO of each test compound was prepared and filtered through a 0.45 μM PVDF 
syringe filter prior to use. A preparation plate (96-well flat bottomed) was prepared by serially diluting 
each compound in order to achieve the desired concentrations (5.0 μM to 200 μM). The test plate was 
prepared by pipetting 196 μL DMSO into wells 1 – 6 and 196 μL PBS/ HEPES into wells 7 – 12. Each 
compound was tested in triplicate thus a single plate was used to evaluate two compounds. 4 μL of 
each compound (Dpa and C1-C12) concentration was pipetted from the preparation plate into the 
test plate in order to bring the total volume up to 200 μL and to ensure that a 2 % (v/v) DMSO/PBS 
and 2 % (v/v) DMSO/HEPES solution is achieved. Test plates were prepared in duplicate and the plates 
were incubated at room temperature (25 °C). The test plates were incubated for 2 hours upon which 
the UV-Vis absorbance readings were measured at 620 nm. The corrected absorbance readings were 
obtained by subtracting the blank readings from each concentration absorbance. 
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3.4.3.  Generation of the aqua species (C1-D2O – C12-D2O) 
Each complex with an equimolar quantity of AgNO3 in deuterium oxide (750 𝜇L) was incubated for 18 
hours at 37 °C.  The solution was then filtered through celite and a drop or two of TMS was added to 
the filtrate as an internal reference analysed with 1H NMR.  
3.4.4.  Reaction of complexes with water 
Each complex in a 75% D2O (750 𝜇L)/ 25% MeOD-d4 (250 𝜇L) mixture was incubated for 18 hours at 
37 °C in the absence of AgNO3. The solution was filtered through celite and a drop or two of TMS was 
added as an internal reference analysed with 1H NMR 3.4.3. was compared with that of the generated 
aqua species (3.4.2.). 
3.4.5.  Evaluation of in vitro activity against 3D7 P. falciparum strain  
Compounds were solubilized in DMSO to a final concentration of 5 mM. The stock solutions of 
compounds were then diluted further in DMSO to generate 3 doses per log dose response dilutions 
within 384-well polypropylene compound storage plates. The dose response dilution plates were then 
diluted 1 µL into 25 µL of sterile water and 5 µL transferred into 384-well imaging plates. The confocal 
image analysis assay is published in detail elsewhere. In brief, the P. falciparum 3D7 strain was kept in 
continuous culture (RPMI supplemented with, 25 mM Hepes, 50 µg/mL hypoxanthine, 2.5 mg/mL 
Albumax II® plus 5% human serum) with sorbitol synchronization performed over two successive intra 
erythrocytic lifecycles to provide ring-stage parasites for use within the assays. On the day of assay, 
ring-stage parasite culture was adjusted to 2% parasitemia and 0.3% hematocrit and 45 µL of which 
was added to the compound-containing imaging plates. The assay plates were incubated for 72 h at 
5% O2, 5% CO2 and 90% N2.  The plates were removed from incubation and allowed to equilibrate at 
room temperature prior to staining with 4',6-diamidino-2-phenylindole (DAPI). The imaging assay 
plates were then imaged on an Opera confocal imaging system. Using Accapella scripting software, 
the number of classified parasites was determined for each assay well. Percent inhibition of parasite 
proliferation was calculated and normalized to assay control data of 0.4% DMSO and 5 µM Puromycin. 
Percent inhibition of parasite numbers (normalized to 5 µM puromycin) was plotted against log 
concentration of the compounds using a 4 parameter log dose, non-linear regression analysis, with 
sigmoidal dose response (variable slope) curve fit using Prizm 4.0. No constraints were placed on the 
top, bottom or Hill slope of the curve fit in the graphing software. 
3.4.6.  Antiplasmodial activity against NF54 P. falciparum strain 
Antiplasmodial testing was done against the drug sensitive strain of P. falciparum, NF54, obtained 
from the Malaria Research and Reference Reagent Resource (MR4) depository22. P. falciparum was 
continuously cultured at 37°C in human O-positive erythrocytes using a modified version of the 
method described by Trager and Jensen23. Culture medium was composed of 10.4 g/L RPMI 1640 (with 
glutamine and without NaHC03), 4 g/L glucose, 6 g/L Hepes buffer, 0.088 g/L hypoxanthine, 5 g/L 
albumax, and 102 ml/L (0.05 g/L) gentamicin (Sigma-Aldrich, Johannesburg, South Africa). Human 
blood, donated by anonymous donors, was obtained from the Western Cape Blood Service (Cape 
Town, South Africa) The half-maximal inhibitory concentration (IC50) of each sample was determined 
using a modified version of the parasite lactate dehydrogenase (pLDH) assay described by 24. The assay 
was performed in duplicate with a 5 point dose-response curve (1/2 serial dilutions) at a concentration 
range of 5.00 – 0.31 µg/mL. The data were analysed by nonlinear regression analysis using the 
GraphPad PRISM version 4.00 program to determine the IC50 of each compound. Chloroquine and 
artesunate (Sigma-Aldrich, Johannesburg, South Africa) were used as reference standards. Two- day 
assays were incubated for 48 hours at 37°C using a culture predominantly in the mature trophozoite 
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stage. Three- day assays were incubated for 72 hours at 37°C using a culture predominantly in the 
immature trophozoite (ring) stage. 
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Conclusions and future work 
4.1.  Conclusions 
Six different metal chlorido- and iodido-bridged dimers, [Ir(Cp*)Cl2]2, [Ir(Cp*)I2]2, [Rh(Cp*)Cl2]2, 
[Rh(Cp*)I2]2, [Ru(p-cymene)Cl2]2 and [Ru(p-cymene)I2]2, were synthesized using reported methods.1,2   
A total of 12 cationic N,N’-chelated half-sandwich organometallic complexes (C1-C12) containing the 
Dpa ligand were then synthesized successfully using an adapted method from Starha et al.3 where C1-
C6 contain the  PF6- counterion and C7-C12 contain the  NO3- counterion.  The complexes (C1-C6)3,4 
have been previously synthesized but was not studied as antiplasmodials previously.   Characterisation 
was done successfully using the analytical techniques, FT-IR, 1H and 13C NMR, XRD, HPLC, CV and mass 
spectrometry. Analysis of the complexes with FTIR showed a shift in the C=N stretching frequencies 
as a result of the coordinated metal pulling away electron density. In addition, the characteristic P-F 
stretch (823-834 cm-1) for complexes C1-C6 and the NO3- symmetric (1299-1317 cm-1) and asymmetric 
(764-771 cm-1) stretching bands for C7-C12 were observed.  Analysis of complexes C7-C12 by 1H NMR 
accounted for all the protons. Due to symmetry of the dipyridylamine ligand, each peak in the aromatic 
region resonated for two chemically equivalent protons. A general downfield shift of three pyridyl 
peaks, integrated for six protons, after metalation was observed upon comparison to Dpa attributed 
to incorporation of the metal to the ligand. The presence of the p- cymene and Cp* moiety was also 
detected.  Analysis of novel complexes C7-C12 by 13C NMR accounted for all carbon atoms. The least 
shielded carbons in the aromatic region were the amine carbons C6 and C8. Mass spectrometry results 
of the NO3- complexes displayed the [M]+ in positive ESI mode.  HPLC purity analysis on all complexes 
confirmed good purity in the range 95-99%. Single crystal structures of complexes (C1, C2, C7, and C9) 
were solved using single crystal X-ray diffraction, substantiating the isolation of the desired N,N’  
complexes. Complexes adopted pseudo-octahedral piano-stool geometry, a well-known geometry for 
half-sandwich organometallic complexes. Bond angles and bond lengths calculated were in agreement 
with similar complexes that have been reported. The electrochemistry of complexes C1-C6 was 
studied by the use of the cyclic voltammetry technique. The obtained voltammogram of Dpa ligand 
showed that it was redox active but did not undergo any redox reactions. An oxidation reaction was 
observed for each complex. The iridium (C1 and C4) and rhodium complexes (C2 and C5) went from 
oxidation state of (III) to (IV). The ruthenium(II) complexes C3 and C6 also underwent an oxidation to 
Ru(III). Reductions observed could be attributed to the halogenido ligands being cleaved off.  
The kinetic solubility and hydrolysis studies of the complexes were investigated. This involved 
determining the aqueous solubility of all complexes and ligand in two different buffers, i.e., PBS and 
HEPES, where one buffer mimics physiological conditions of the host (body) and the other is used in 
in vitro assays, respectively. A highly soluble compound, hydrocortisone and low soluble compound 
reserpine were used as positive and negative controls, respectively. A high throughput in vitro kinetic 
assay was done on all the complexes and Dpa ligand. Form the assay results, it was found that the PF6 
complexes, C1-C6, had a different range of solubilities from poor solubility to good solubility in both 
buffers. The NO3- complexes on the other hand had good solubility in both buffer solutions with the 
exception of complex C10, it exhibited moderate to good solubility in the HEPES buffer. A study on 
whether complexes will readily hydrolyse in aqueous based medium was done. This involved 
generation an aqua species by incubating each complex with equimolar quantity of AgNO3 in D2O for 
18 hours at 37 °C. The 1H NMR spectra of this generated aqua species was then compared to that the 
incubated species in 75% D2O (750 𝜇L)/ 25% MeOD-d4 (250 𝜇L) without AgNO3. Results obtained 
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showed that aquation studies of the complexes resulted in only one iodide complex C12 undergoing 
aquation. The ability of the chlorido complexes C2, C3, C8, C9 and C12 to hydrolyse over the iodine 
complexes C1, C5, C6, C10 and C11 can be attributed to the relatively larger ionic radii of iodine which 
may block/ prevent hydrolysis from occurring due to an increase in the nephelauxetic effect. A greater 
electron cloud expansion of the metal onto the iodide ligand makes the bond between the metal and 
iodide ligand more covalent, whereas that of the metal and chlorine is more ionic. All but one chloride 
complex (C7) underwent aquation. Although aquation occurred, complexes that did display the ability 
to hydrolyse in solution, did not do so to completion, only a fraction of the complexes hydrolysed 
according to the peak intensities of the aqua species observed.  
A study on the in vitro biological activity of complexes C1-C6 against 3D7 and NF54 P. falciparum 
strains was conducted. The antimalarial activity of complexes C7-C12 could not be obtained due to 
time constraints. When the complexes were tested against the CQ sensitive strain, 3D7, it was found 
that the ligand was inactive whereas the complexes did show some activity, however, the activity was 
not great. Complexes showed activity in the order C2 > C5 > C6 > C4 > C3 > C1. Rhodium complexes C2 
and C5 showed the best activity in relation to the other complexes. Iridium complexes showing the 
least activity with C4 showing slightly less activity than ruthenium complex C3.  A comparison of each 
chlorido derivative to its iodido analogue showed that the activity could be correlated with the 
complexes’ solubility in HEPES buffer since the evaluation assay involves the use of it. It was 
established that for relatively more soluble complexes in HEPES, the better activity will be exhibited 
by the drug. This is by reason of concentration of complex available in solution to provide efficacy. The 
more soluble complexes C4, C2 and C6 showed better activity than their chlorido/ iodido derivative. 
Incorporation of the metals into the organic scaffold did show improved activity. Evaluation of 
complexes C1-C6 against drug sensitive NF54 P. falciparum strain of malaria showed them to be 
inactive following a two- and three- day assay. It was concluded that this inactivity was attributed to 
the use of hypoxanthine in the growth media which offset the complexes’ moa resulting in a lag time. 
Perhaps if an assay longer than a three- day assay was utilized; some activity of these complexes would 
have been observed. Complexes C1-C6 may show activity at high mass concentration tested since they 
have high molecular weights, their molar concentration at 5 𝜇g/mL is much lower than an organic 
molecule with a lower molecular weight. 
4.2.  Future work: 
Crystals of complexes C8, C10, C11 and C12 could be grown and their crystal structures solved. With 
the use of single crystal X-ray diffraction, we are able to confirm that proposed the structures of the 
complexes were synthesized successfully, coordinating through the nitrogens of the pyridine rings and 
having the correct counterion. In terms of the DMSO interaction studies, the minimum number of 
equivalents required for the complete displacement of all chlorido or iodido ligands for DMSO needs 
to be investigated further for all complexes. This can be done by preparing a 1mM stock solution of 
each complex in dichloromethane (DCM) and a 4mM stock solution of DMSO could be added in small 
increments until the reaction reaches its endpoint. After each addition, the 1H NMR spectrum of the 
sample would then be recorded. In this way, the NMR spectra could be monitored for any changes in 
order to determine whether any interaction does occur between each complex and DMSO. If the 
complex is found to interact with DMSO, the number of equivalents of DMSO required for the reaction 
to reach its endpoint could be determined. Other counterions could be investigated for this series of 
complexes in order to see what effect it will have on physicochemical properties, activity as well as 
cytotoxicity of the complexes. The electrochemistry of nitrate complexes C7-C12 ned to be investigate 
using cyclic voltammetry. 
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The in vitro biological activity of C7-C12 against 3D7 P. falciparum strains needs to be evaluated in 
order to assess the effect of counterion exchange on the activity. It will also be interesting to see these 
compounds activity as they exhibit far better solubility in aqueous based medium. Testing against the 
NF54 malaria strains could be repeated for complexes C1-C6 (i) for an extended duration to account 
for the lag time, (ii) at higher concentrations (iii) hypoxanthine not to be used in the growth medium. 
This would have to be done for the nitrate counterion complexes (C7-C12) as well. In vitro cytotoxicity 
of known complexes C1-C6 was only reported to have been performed against human ovarian 
carcinoma cell line, A2780, by Starha3,4 and not against healthy cell lines. Cytotoxicity testing against 
healthy cell lines would have to be carried out for known complexes as well as novel complexes C7-
C12. 
Furthermore, more structure activity studies could be done. This could involve the synthesis of C,N 
half-sandwich organometallic complexes of ligand N-phenyl-2-pyridinamine (Scheme 4.1 below) in an 
attempt to improve the therapeutic efficacy of the complexes.  Modification of the ligand from N’N to C’N 
has been reported to improve in vitro anticancer activity.5 
 
Scheme 4.3: Reaction scheme for the synthesis of N-phenyl-2-pyridinamine complexes. 
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